Medicine – Parkinsonism

Parkinsonism is a clinical syndrome characterised mainly by bradykinesia together with rigidity and/or resting tremor, usually caused by impaired dopaminergic function within the nigrostriatal pathway of the basal ganglia.

The commonest cause is idiopathic Parkinson disease, but several drugs, toxins, neurodegenerative disorders, and structural neurological conditions can produce a similar syndrome.

1. Dopamine Deficiency

In Parkinson disease, there is progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta.

These neurons normally project to the striatum, particularly the caudate nucleus and putamen.

Loss of these neurons causes:

Reduced dopamine in the nigrostriatal pathway → impaired basal ganglia motor control → bradykinesia, rigidity and tremor.

So the important site is not simply “dopamine deficiency in the substantia nigra,” but rather loss of substantia nigra neurons causing reduced dopamine delivery to the striatum.

2. Lewy Bodies

A classic pathological feature of idiopathic Parkinson disease is the presence of Lewy bodies within affected neurons.

Lewy bodies are intracellular inclusions composed largely of abnormal aggregates of alpha-synuclein.

They are particularly associated with degeneration in the substantia nigra but can also be found in other regions of the nervous system.

3. Core Motor Features

The classic motor syndrome consists of:

Bradykinesia.

Rigidity.

Resting tremor.

Postural instability may occur later in the disease.

Modern diagnostic approaches generally require bradykinesia as a central feature of parkinsonism.

4. Resting Tremor

The typical Parkinson tremor occurs mainly at rest.

It often begins asymmetrically in one hand and may resemble the repetitive movement of rolling a small object between the thumb and fingers.

This is the classic pill-rolling tremor.

5. Characteristics of Parkinson Tremor

Typical features include:

Resting tremor.

Usually asymmetric at onset.

Frequency commonly around 4–6 Hz.

Reduced during voluntary movement.

Disappears during sleep.

The older figure of 3–5 Hz is close, but 4–6 Hz is a commonly used modern description.

Stress or emotional tension may make the tremor more obvious.

6. Bradykinesia

Bradykinesia means slowness of movement and is one of the most important features of Parkinsonism.

Patients may have difficulty initiating movement and may progressively reduce the speed and amplitude of repetitive movements.

Examples include:

Slow walking.

Difficulty turning in bed.

Reduced spontaneous movement.

Slow dressing and eating.

Difficulty starting to walk.

7. Hypokinesia and Akinesia

Bradykinesia is often accompanied by:

Hypokinesia – reduced amplitude of movement.

Akinesia – difficulty initiating movement or episodes of temporary inability to move.

These features contribute to freezing and gait difficulty in more advanced disease.

8. Rigidity

Rigidity is increased resistance to passive movement of a limb.

Unlike spasticity, Parkinsonian rigidity is not strongly dependent on the speed of movement.

Two classic patterns are described.

9. Lead-Pipe Rigidity

Lead-pipe rigidity produces smooth, sustained resistance throughout the range of passive movement.

The examiner feels continuous stiffness when moving the patient’s limb.

10. Cogwheel Rigidity

Cogwheel rigidity produces a ratchet-like or jerky resistance during passive movement.

It is thought to result from rigidity combined with an underlying tremor.

This is particularly characteristic of Parkinsonism.

11. Expressionless Face

Patients may develop reduced spontaneous facial movement, producing a relatively expressionless or mask-like face.

This is called hypomimia.

Blinking may also become less frequent.

12. Speech Changes

Speech may become:

Quiet.

Monotonous.

Rapid or indistinct.

Reduced voice volume is called hypophonia.

Patients may also have difficulty articulating clearly as the disease progresses.

13. Festinant and Shuffling Gait

Parkinsonian gait is typically short-stepped and shuffling.

Patients may walk with:

Reduced arm swing.

Stooped posture.

Short steps.

Difficulty initiating gait.

Difficulty turning.

14. Festination

Festination refers to progressively faster, shorter steps as the patient appears to chase the body’s centre of gravity.

The patient may lean forward and seem unable to stop easily.

Therefore, festination is related to but not exactly identical to a simple shuffling gait.

15. Freezing of Gait

Patients may experience freezing, particularly when:

Starting to walk.

Turning.

Passing through narrow doorways.

Approaching obstacles.

The feet may appear temporarily “stuck to the floor.”

16. Reduced Arm Swing

Loss of normal arm swing during walking is an early and useful clue.

It may be more marked on one side, reflecting the typical asymmetrical onset of Parkinson disease.

17. Micrographia

Micrographia means progressively small handwriting.

As the patient continues writing, the letters may become smaller and more cramped.

It reflects bradykinesia and reduced amplitude of repetitive movement.

18. Dysphagia

Difficulty swallowing may develop because of impaired coordination and bradykinesia of the bulbar muscles.

Dysphagia can lead to:

Choking.

Weight loss.

Aspiration.

Aspiration pneumonia.

It becomes particularly important in more advanced disease.

19. Postural Instability

Postural reflexes may become impaired later in Parkinson disease.

This can cause:

Poor balance.

Falls.

Difficulty recovering after being pushed.

Early severe postural instability should raise suspicion for an atypical Parkinsonian disorder rather than uncomplicated idiopathic Parkinson disease.

20. Autonomic Dysfunction

Autonomic symptoms are common.

These can include:

Postural hypotension.

Constipation.

Urinary dysfunction.

Sexual dysfunction.

Excessive sweating.

Orthostatic hypotension may result from the disease itself or be worsened by dopaminergic medication.

21. Depression

Depression is common in Parkinson disease and may occur before or after motor symptoms begin.

The old figure of about 30% is a reasonable historical approximation, but prevalence varies depending on definitions and patient population.

Depression should be regarded as an important non-motor manifestation, not merely a psychological reaction to disability.

22. Other Non-Motor Features

Parkinson disease is a multisystem disorder.

Other important non-motor symptoms include:

Anosmia or hyposmia.

REM sleep behaviour disorder.

Constipation.

Fatigue.

Anxiety.

Cognitive impairment.

Hallucinations.

Sleep disturbance.

Some of these can precede the motor syndrome by years.

23. Idiopathic Parkinson Disease

Idiopathic Parkinson disease is the commonest cause of Parkinsonism.

It typically begins asymmetrically and progresses gradually.

A good clinical response to levodopa supports the diagnosis.

24. Drug-Induced Parkinsonism

A common secondary cause is drug-induced Parkinsonism, particularly from medications that block dopamine receptors.

Important examples include some:

Antipsychotic drugs.

Antiemetic dopamine antagonists.

Examples include metoclopramide and prochlorperazine.

Drug-induced Parkinsonism is often more symmetrical than idiopathic Parkinson disease.

25. Dementia Pugilistica

The older term dementia pugilistica refers to neurological damage associated with repeated head trauma, historically described in boxers.

The broader modern concept is chronic traumatic encephalopathy (CTE).

Repeated head injury can produce cognitive, behavioural, and motor abnormalities, including Parkinsonian features in some patients.

26. Post-Encephalitic Parkinsonism

Parkinsonism can occur after encephalitic illness.

Historically, this was particularly associated with encephalitis lethargica, although this is now rare.

Damage to basal ganglia structures can lead to persistent Parkinsonian symptoms.

27. Normal-Pressure Hydrocephalus

Normal-pressure hydrocephalus (NPH) can produce a gait disorder that may resemble Parkinsonism.

The classic triad is:

Gait disturbance.

Cognitive impairment.

Urinary incontinence.

The gait is often broad-based, short-stepped, and described as “magnetic.”

Prominent resting tremor is less typical than in idiopathic Parkinson disease.

28. Toxin-Induced Parkinsonism

Several toxins can damage dopaminergic pathways and produce Parkinsonism.

Important examples include:

MPTP.

Carbon monoxide.

Manganese.

Some other toxic exposures may also contribute depending on dose and duration.

29. MPTP

MPTP is a neurotoxin that selectively damages dopaminergic neurons in the substantia nigra.

It produces a syndrome that can closely resemble idiopathic Parkinson disease.

Its discovery played an important role in understanding Parkinson disease pathophysiology.

30. Carbon Monoxide

Severe carbon monoxide poisoning can damage the basal ganglia, particularly the globus pallidus.

Delayed neurological complications may include:

Parkinsonism.

Cognitive impairment.

Movement disorders.

31. Manganese

Chronic manganese exposure can cause a Parkinsonian syndrome.

However, the pattern may differ somewhat from idiopathic Parkinson disease, with more prominent gait and postural abnormalities and less classic resting tremor.

32. Narcotics

The original note lists “narcotics” as a cause.

This is too broad.

Most opioids do not directly cause classical chronic Parkinsonism.

The historically important association is with MPTP contamination in illicit drug exposure, which can produce profound Parkinsonism.

Therefore, it is better to remember MPTP specifically rather than “narcotics” in general.

33. Wilson Disease

Wilson disease is an important cause of Parkinsonian symptoms in younger patients.

It results from abnormal copper metabolism due to mutations in ATP7B.

Neurological features may include:

Tremor.

Rigidity.

Dystonia.

Dysarthria.

Parkinsonism.

The presence of Kayser–Fleischer rings and liver disease can provide important clues.

34. Other Atypical Parkinsonian Disorders

Not every patient with Parkinsonism has idiopathic Parkinson disease.

Important atypical neurodegenerative causes include:

Multiple system atrophy.

Progressive supranuclear palsy.

Corticobasal syndrome.

Dementia with Lewy bodies.

These conditions often respond less well to levodopa and may have additional early neurological features.

35. Multiple System Atrophy

Multiple system atrophy (MSA) combines Parkinsonism with prominent autonomic dysfunction and sometimes cerebellar or pyramidal signs.

Early severe postural hypotension, urinary dysfunction, and poor levodopa response may suggest MSA.

36. Progressive Supranuclear Palsy

Progressive supranuclear palsy (PSP) can cause:

Parkinsonism.

Early falls.

Axial rigidity.

Vertical gaze palsy.

The levodopa response is usually limited.

37. Dementia with Lewy Bodies

Dementia with Lewy bodies may cause Parkinsonism together with:

Early cognitive impairment.

Fluctuating cognition.

Visual hallucinations.

REM sleep behaviour disorder.

When dementia occurs before or within about a year of Parkinsonism, dementia with Lewy bodies is generally considered rather than Parkinson disease dementia.

38. Diagnosis

Parkinson disease is primarily a clinical diagnosis.

There is no single routine blood test that confirms it.

Diagnosis is based on the pattern of bradykinesia, rigidity, tremor, asymmetry, progression, response to levodopa, and absence of features strongly suggesting another disorder.

39. Imaging

Routine brain imaging is not always required to diagnose typical Parkinson disease.

MRI may be useful when the presentation is atypical or when another structural cause needs to be excluded.

Specialised dopamine-transporter imaging can sometimes help distinguish degenerative Parkinsonism from disorders such as essential tremor, but it does not by itself distinguish all Parkinsonian syndromes.

40. Drug Treatment

Drug treatment aims to improve motor symptoms by increasing dopaminergic activity or reducing relative cholinergic activity within the basal ganglia.

The major drug groups include:

Levodopa combined with carbidopa or benserazide.

Dopamine agonists.

MAO-B inhibitors.

COMT inhibitors.

Anticholinergic drugs in selected patients.

41. Levodopa

Levodopa remains the most effective symptomatic treatment for Parkinson motor symptoms.

It is usually combined with carbidopa or benserazide, which reduce peripheral conversion of levodopa into dopamine.

Levodopa is particularly effective for:

Bradykinesia.

Rigidity.

It also frequently improves tremor.

42. Dopamine Agonists

Dopamine agonists include:

Pramipexole.

Ropinirole.

Rotigotine.

Apomorphine in selected advanced disease.

They directly stimulate dopamine receptors and may be used alone or in combination with levodopa.

43. MAO-B Inhibitors

Examples include:

Selegiline.

Rasagiline.

Safinamide.

They inhibit dopamine breakdown and can provide symptomatic benefit or reduce “off” time when used with levodopa.

44. COMT Inhibitors

Examples include:

Entacapone.

Opicapone.

They prolong the effect of levodopa and are particularly useful for end-of-dose wearing-off.

45. Anticholinergic Drugs

Examples include:

Procyclidine.

Benztropine.

They mainly reduce tremor and are sometimes particularly useful in drug-induced Parkinsonism.

Because they can cause confusion, urinary retention, constipation, and blurred vision, they are generally used cautiously, especially in older patients.

46. Non-Drug Management

Management should not rely only on medication.

Important supportive measures include:

Physiotherapy.

Occupational therapy.

Speech and language therapy.

Swallowing assessment.

Exercise programmes.

Falls prevention.

Management of depression, sleep problems, constipation, and autonomic symptoms.

47. Advanced Treatment

Selected patients with advanced Parkinson disease and motor fluctuations despite optimal medication may be considered for treatments such as:

Deep brain stimulation.

Continuous apomorphine infusion.

Continuous levodopa-based infusion therapies.

These require specialist assessment.

48. Parkinsonism – Note Form

Pathology in Parkinson disease: degeneration of dopaminergic neurons in substantia nigra pars compacta.

Result: reduced dopamine in the striatum.

Pathological hallmark: Lewy bodies containing alpha-synuclein.

Core feature: bradykinesia.

Resting tremor: pill-rolling, usually asymmetric, around 4–6 Hz, reduced with movement and absent during sleep.

Rigidity: lead-pipe or cogwheel.

Face: hypomimia or mask-like expression.

Gait: short, shuffling steps with reduced arm swing; festination and freezing may occur.

Writing: micrographia.

Swallowing: dysphagia may occur.

Autonomic symptoms: postural hypotension, constipation and urinary dysfunction.

Psychiatric feature: depression is common.

Idiopathic cause: Parkinson disease.

Drug-induced: dopamine receptor antagonists, especially antipsychotics and some antiemetics.

Trauma: chronic repetitive head injury may cause Parkinsonian features.

NPH: gait disturbance + cognitive decline + urinary incontinence.

Toxins: MPTP, carbon monoxide and manganese.

Young patient: consider Wilson disease.

Treatment: levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and selected anticholinergics.

Key Clinical Pattern

Remember Parkinsonism as:

Bradykinesia + resting tremor + rigidity.

The classic patient has:

Asymmetric pill-rolling resting tremor.

Cogwheel rigidity.

Slow movements.

Reduced facial expression.

Micrographia.

Shuffling gait with reduced arm swing.

The underlying mechanism in idiopathic Parkinson disease is:

Substantia nigra degeneration → ↓ striatal dopamine → impaired basal ganglia motor control.

And the major secondary causes to remember are:

Dopamine-blocking drugs + NPH + toxins + Wilson disease + atypical neurodegenerative disorders.

Medicine – Drugs Used in Parkinsonism

Drug treatment of Parkinson disease aims mainly to restore the imbalance between dopaminergic and cholinergic activity within the basal ganglia. The major motor manifestations—bradykinesia, rigidity, resting tremor, and later postural instability—result largely from degeneration of dopaminergic neurons in the substantia nigra pars compacta, causing reduced dopamine within the striatum.

The drugs in your table can be organised into five important groups: levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors, and anticholinergic drugs. Some details in the older table need updating because modern Parkinson treatment has changed considerably.

1. Levodopa

Levodopa (L-DOPA) is the metabolic precursor of dopamine and remains the most effective symptomatic treatment for the motor features of Parkinson disease, particularly bradykinesia and rigidity.

Dopamine itself cannot effectively cross the blood–brain barrier. Levodopa, however, can cross into the CNS and is then converted into dopamine by DOPA decarboxylase.

Therefore:

Levodopa crosses blood–brain barrier → converted to dopamine in brain → replenishes striatal dopamine → improves Parkinsonian motor symptoms.

2. Levodopa with Carbidopa or Benserazide

Levodopa is almost always given with a peripheral DOPA-decarboxylase inhibitor, such as:

Carbidopa.

Benserazide.

These drugs inhibit the peripheral conversion of levodopa into dopamine but do not significantly cross the blood–brain barrier.

Consequently, more levodopa reaches the CNS and peripheral dopaminergic adverse effects are reduced.

3. Why Levodopa Is Not Given Alone

If levodopa were given alone, a substantial amount would be converted into dopamine in peripheral tissues before reaching the brain.

Peripheral dopamine can cause adverse effects such as:

Nausea and vomiting.

Postural hypotension.

Cardiovascular effects.

Adding carbidopa or benserazide therefore both increases CNS availability of levodopa and reduces peripheral adverse effects.

4. Effects of Levodopa

Levodopa is particularly effective at improving:

Bradykinesia.

Rigidity.

It also improves tremor in many patients.

Its effect on later problems such as postural instability, freezing, speech disturbance, and some non-motor manifestations may be less predictable.

5. Motor Fluctuations with Levodopa

After prolonged treatment, patients may develop motor fluctuations.

One important pattern is wearing-off, in which the effect of each levodopa dose becomes progressively shorter.

The patient improves after taking a dose but develops recurrent Parkinsonian symptoms before the next dose is due.

This is sometimes called end-of-dose deterioration.

6. On–Off Phenomenon

Patients receiving long-term levodopa may also experience an on–off phenomenon.

During an “on” period, mobility is relatively good and the medication is working effectively.

During an “off” period, Parkinsonian symptoms suddenly become much more prominent, with severe bradykinesia or inability to move.

These fluctuations can become unpredictable in advanced disease.

7. Levodopa-Induced Dyskinesia

Long-term levodopa therapy can produce dyskinesias, meaning involuntary abnormal movements.

These are often choreiform or writhing movements and commonly occur when levodopa concentrations are relatively high.

Thus:

Long-term levodopa → motor fluctuations + dyskinesias.

8. Neuropsychiatric Effects of Levodopa

Dopaminergic treatment may cause neuropsychiatric complications, particularly in older or cognitively vulnerable patients.

These can include:

Hallucinations.

Confusion.

Vivid dreams.

Psychotic symptoms.

Hallucinations are therefore an important adverse effect to remember.

9. Dopamine Agonists

Dopamine agonists directly stimulate dopamine receptors and therefore do not require conversion into dopamine.

The older table lists:

Bromocriptine.

Pergolide.

These are older ergot-derived dopamine agonists and are now much less commonly used for Parkinson disease because of their adverse-effect profiles.

10. Modern Dopamine Agonists

More commonly encountered modern dopamine agonists include:

Pramipexole.

Ropinirole.

Rotigotine.

Apomorphine is another dopamine agonist used in selected patients, particularly for troublesome “off” episodes or advanced disease.

11. Mechanism of Dopamine Agonists

Dopamine agonists directly stimulate dopamine receptors in the basal ganglia.

Many have substantial activity at the D₂-family of dopamine receptors.

They can improve:

Bradykinesia.

Rigidity.

Tremor.

They may be used alone in selected patients or together with levodopa.

12. Advantages of Dopamine Agonists

Dopamine agonists have longer pharmacological effects than levodopa and can sometimes reduce “off” time when added to levodopa.

However, they are generally less effective than levodopa for overall motor symptom control and often produce more troublesome neuropsychiatric and behavioural adverse effects.

13. Adverse Effects of Dopamine Agonists

Important adverse effects include:

Nausea.

Postural hypotension.

Hallucinations.

Confusion.

Somnolence and sudden sleep attacks.

Peripheral oedema.

14. Impulse-Control Disorders

An especially important adverse effect of dopamine agonists is the development of impulse-control disorders.

These may include:

Pathological gambling.

Compulsive shopping.

Binge eating.

Hypersexuality.

Patients and families should therefore be warned about potentially major behavioural changes.

15. Fibrotic Reactions with Older Dopamine Agonists

The table correctly lists fibrotic reactions, but these are particularly associated with the older ergot-derived dopamine agonists, such as bromocriptine and pergolide.

They may cause:

Pleuropulmonary fibrosis.

Retroperitoneal fibrosis.

Cardiac valvular fibrosis.

This is an important reason why pergolide is no longer routinely used in many countries and non-ergot dopamine agonists are generally preferred.

16. Selegiline

Selegiline is a selective monoamine oxidase-B (MAO-B) inhibitor.

MAO-B is involved in dopamine metabolism within the brain.

By inhibiting MAO-B:

Dopamine breakdown ↓ → dopamine availability in the brain ↑ → Parkinsonian symptoms improve.

17. Other MAO-B Inhibitors

Other drugs in this class include:

Rasagiline.

Safinamide.

These agents may be used alone in selected early disease or as adjuncts to levodopa to reduce motor fluctuations.

18. Does Selegiline Slow Disease Progression?

The original table states that selegiline “may slow progression of disease.”

This should be updated.

MAO-B inhibitors provide symptomatic benefit, but convincing evidence that selegiline meaningfully prevents or reverses the underlying neurodegenerative progression of Parkinson disease is lacking.

Therefore, it is better remembered as a symptomatic and adjunctive treatment, rather than a proven neuroprotective treatment.

19. Adverse Effects of Selegiline

Potential adverse effects include:

Postural hypotension.

Hallucinations.

Confusion.

Nausea.

Dyskinesia when combined with levodopa.

Because selegiline has metabolites with stimulant properties, it may also contribute to insomnia, particularly if taken late in the day.

20. Entacapone

Entacapone is a catechol-O-methyltransferase (COMT) inhibitor.

It is used together with levodopa rather than as effective Parkinson therapy on its own.

COMT normally contributes to the peripheral metabolism of levodopa.

21. Mechanism of Entacapone

Entacapone inhibits peripheral COMT and therefore reduces the breakdown of levodopa.

This results in:

Reduced peripheral levodopa metabolism → prolonged levodopa availability → more sustained dopaminergic effect.

It is particularly useful for patients who experience end-of-dose wearing-off.

22. Entacapone and Wearing-Off

A patient may initially respond well to levodopa but find that symptoms return before the next dose.

Adding entacapone can extend the duration of each levodopa dose.

Therefore:

Levodopa wearing-off → consider a COMT inhibitor such as entacapone.

23. Adverse Effects of Entacapone

Important adverse effects include:

Diarrhoea.

Nausea.

Postural hypotension.

Increased levodopa-related dyskinesia.

Entacapone can also cause harmless orange-brown or reddish-brown discoloration of urine.

The old table describes this simply as “brown urine.”

24. Other COMT Inhibitors

Other COMT inhibitors include:

Opicapone.

Tolcapone.

Tolcapone acts both centrally and peripherally but is used much less because of the risk of serious hepatotoxicity and the need for appropriate liver monitoring.

25. Anticholinergic Drugs

Anticholinergic drugs used in Parkinsonism are predominantly central antimuscarinic agents.

Examples from the table include:

Benztropine.

Procyclidine.

Another traditional example is trihexyphenidyl (benzhexol).

26. Mechanism of Anticholinergic Drugs

Loss of dopamine in Parkinson disease creates a relative excess of cholinergic activity within the basal ganglia.

Antimuscarinic drugs reduce this cholinergic influence.

They are particularly useful for reducing:

Tremor.

Rigidity to some extent.

They have relatively little effect on bradykinesia.

27. Drug-Induced Parkinsonism

Anticholinergic drugs can be particularly useful for drug-induced Parkinsonism, such as Parkinsonian symptoms caused by dopamine-blocking antipsychotic drugs.

However, the underlying medication should also be reviewed whenever possible.

They are not usually preferred as routine first-line treatment for typical Parkinson disease, particularly in older patients.

28. Adverse Effects of Anticholinergic Drugs

Because these drugs block muscarinic acetylcholine receptors, they produce characteristic anticholinergic adverse effects:

Dry mouth.

Constipation.

Urinary retention.

Blurred vision.

Tachycardia.

29. Psychiatric and Cognitive Effects

Central anticholinergic effects can cause:

Confusion.

Memory impairment.

Hallucinations.

Agitation.

Because these effects are particularly problematic in older patients, anticholinergic drugs are generally avoided or used very cautiously in elderly people or patients with cognitive impairment.

30. Drugs Used in Parkinsonism – Note Form

Levodopa + carbidopa/benserazide: levodopa enters the brain and is converted to dopamine; the peripheral decarboxylase inhibitor prevents excessive peripheral conversion.

Main benefit of levodopa: strongest symptomatic improvement, particularly for bradykinesia and rigidity.

Major long-term levodopa problems: wearing-off, on–off fluctuations and dyskinesia.

Other levodopa adverse effects: nausea, postural hypotension, hallucinations and confusion.

Dopamine agonists: directly stimulate dopamine receptors.

Modern dopamine agonists: pramipexole, ropinirole and rotigotine; apomorphine is important in selected advanced disease.

Major dopamine-agonist adverse effects: hallucinations, hypotension, sleep attacks and impulse-control disorders.

Bromocriptine/pergolide: older ergot dopamine agonists associated with fibrotic complications; pergolide is largely obsolete in modern Parkinson treatment.

Selegiline: MAO-B inhibitor → decreases dopamine breakdown.

MAO-B inhibitors: provide symptomatic benefit but should not be regarded as proven treatments that stop Parkinson disease progression.

Entacapone: COMT inhibitor → reduces peripheral levodopa metabolism and prolongs levodopa action.

Best use of entacapone: end-of-dose wearing-off.

Entacapone adverse effects: diarrhoea, dyskinesia and harmless urine discoloration.

Anticholinergics: benztropine and procyclidine.

Anticholinergic benefit: mainly improve tremor; relatively little effect on bradykinesia.

Anticholinergic adverse effects: dry mouth, urinary retention, constipation, blurred vision, tachycardia, confusion and psychiatric disturbance.

Key Clinical Pattern

The easiest way to remember Parkinson drugs is according to where they increase dopaminergic activity:

Levodopa → supplies the precursor for dopamine.

Dopamine agonists → directly stimulate dopamine receptors.

MAO-B inhibitors → reduce dopamine breakdown in the brain.

COMT inhibitors → prolong the effect of levodopa.

Anticholinergics → reduce relative cholinergic activity, particularly helping tremor.

For examinations, remember the characteristic drug–adverse effect associations:

Levodopa → dyskinesia + on–off fluctuations + hallucinations.

Dopamine agonists → impulse-control disorders + hallucinations + sleep attacks.

Selegiline → postural hypotension + hallucinations ± insomnia.

Entacapone → diarrhoea + urine discoloration + increased dyskinesia.

Anticholinergics → dry mouth + constipation + urinary retention + confusion.

Medicine – Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe, progressive X-linked recessive muscular dystrophy caused by pathogenic variants in the DMD gene, resulting in an almost complete absence of functional dystrophin protein.

Because dystrophin is essential for maintaining the structural stability of muscle fibres during contraction, its absence leads to repeated muscle-fibre injury, degeneration, and replacement by fat and connective tissue.

1. Inheritance

DMD is inherited in an X-linked recessive pattern.

It therefore predominantly affects boys, while females are usually carriers.

Some female carriers can develop mild muscle weakness or cardiomyopathy because of skewed X-chromosome inactivation.

2. Dystrophin Deficiency

The DMD gene encodes dystrophin, a structural protein that links the muscle-cell cytoskeleton to the surrounding extracellular matrix.

In Duchenne muscular dystrophy, functional dystrophin is essentially absent.

This makes the muscle membrane fragile during contraction and results in progressive muscle-cell damage.

3. Comparison with Becker Muscular Dystrophy

Duchenne and Becker muscular dystrophy are caused by mutations in the same gene.

The key difference is:

Duchenne muscular dystrophy → dystrophin absent or nearly absent.

Becker muscular dystrophy → dystrophin reduced or structurally abnormal but partly functional.

As a result, Duchenne disease presents earlier and is more severe.

4. Age of Presentation

Symptoms usually become apparent in early childhood, often between about 2 and 5 years of age.

Parents may notice delayed motor milestones, frequent falls, difficulty running, or difficulty climbing stairs.

5. Girdle Muscle Weakness

The weakness is predominantly proximal, especially affecting the pelvic-girdle muscles.

Children may have difficulty:

Running.

Jumping.

Climbing stairs.

Getting up from the floor.

Keeping up with other children.

As weakness progresses, the shoulder-girdle muscles also become affected.

6. Waddling Gait

Weakness of the hip abductor and pelvic-girdle muscles causes a characteristic waddling gait.

The child shifts the trunk from side to side while walking to compensate for weak hip muscles.

Lumbar lordosis may also become more pronounced.

7. Gowers Sign

A classic clinical finding is Gowers sign.

When rising from the floor, the child uses the hands to push on the knees and then “climbs” up the thighs.

This occurs because the hip and thigh muscles are too weak to raise the body efficiently without assistance from the upper limbs.

Therefore:

Gowers sign = proximal pelvic-girdle weakness.

8. Calf Pseudohypertrophy

The calf muscles may appear unusually large.

This is called calf pseudohypertrophy.

The enlargement is not caused by increased functional muscle tissue. Instead, damaged muscle fibres are progressively replaced by fat and connective tissue.

Thus:

Large calves + weak child → think Duchenne muscular dystrophy.

9. Raised Creatine Kinase

Serum creatine kinase (CK) is typically markedly elevated, often many times above the normal range.

CK leaks from damaged muscle fibres into the blood.

The CK may be very high even before severe weakness becomes obvious.

10. Other Laboratory Findings

Other muscle-derived enzymes may also be elevated, including:

AST.

ALT.

This is important because elevated transaminases in a child with muscle weakness may be mistakenly interpreted as primary liver disease.

A markedly elevated CK points toward skeletal-muscle injury.

11. Loss of Walking Ability

Without effective modern disease-modifying management, boys with classic DMD historically lost independent walking ability around the early teenage years, often near 12 years of age.

However, this older figure is no longer absolute.

Modern corticosteroid therapy, rehabilitation, cardiac care, respiratory support, and newer targeted treatments can prolong ambulation and survival.

12. Contractures

As muscle weakness progresses, patients may develop joint contractures.

Common sites include:

Ankles.

Knees.

Hips.

Tightness of the Achilles tendons may contribute to toe walking.

Regular stretching and physiotherapy are important to delay contracture formation.

13. Scoliosis

Loss of trunk muscle strength can lead to scoliosis, particularly after loss of independent ambulation.

Severe scoliosis can further impair respiratory mechanics.

Postural management and orthopaedic assessment are therefore important.

14. Respiratory Muscle Weakness

Progressive weakness eventually affects the respiratory muscles.

This can cause:

Weak cough.

Poor secretion clearance.

Recurrent chest infections.

Nocturnal hypoventilation.

Progressive respiratory failure.

Respiratory complications were historically a major cause of death.

15. Cardiac Involvement

Dystrophin is also important in cardiac muscle.

Patients commonly develop dilated cardiomyopathy.

They may also develop:

Left ventricular dysfunction.

Cardiac fibrosis.

Arrhythmias.

Cardiac disease may progress even when skeletal-muscle symptoms dominate clinically.

16. Cardiac Monitoring

Regular cardiac surveillance is therefore essential.

This may include:

ECG.

Echocardiography.

Cardiac MRI.

Early treatment of cardiomyopathy can improve long-term outcomes.

17. Cognitive and Neurodevelopmental Features

Dystrophin is also expressed in the brain.

Some boys with DMD may have:

Learning difficulties.

Attention problems.

Autism-spectrum features.

Speech or language delay.

Intellectual ability varies widely, and severe cognitive impairment is not universal.

18. Diagnosis

Diagnosis is usually established by:

Clinical features.

Very high serum CK.

Genetic testing for pathogenic variants in the DMD gene.

Genetic confirmation is important because it establishes the diagnosis and may determine eligibility for mutation-specific therapies.

19. Muscle Biopsy

Muscle biopsy is now less commonly required when genetic testing confirms the diagnosis.

When performed, it may demonstrate severe dystrophic changes and absence of dystrophin on immunostaining.

20. Genetic Counselling

Because DMD is X-linked, genetic counselling is important.

Carrier testing may be offered to appropriate female relatives.

Carrier women may also require cardiac surveillance because they can develop cardiomyopathy even without significant skeletal-muscle weakness.

21. Corticosteroid Therapy

Corticosteroids such as prednisolone or deflazacort have long been used to slow the decline in muscle strength.

They can help:

Prolong walking ability.

Preserve upper-limb function.

Delay scoliosis.

Support respiratory function.

Treatment requires monitoring for long-term adverse effects.

22. Modern Disease-Modifying Therapy

Management has expanded beyond supportive care.

Selected patients may be eligible for mutation-specific treatments, including exon-skipping therapies or other targeted approaches, depending on the exact DMD gene variant and local regulatory approval.

Gene-based treatments are also an evolving area of DMD management.

23. Respiratory Management

Respiratory care includes:

Regular pulmonary-function assessment.

Airway-clearance techniques.

Assisted cough when needed.

Non-invasive ventilation for nocturnal hypoventilation or respiratory failure.

These interventions have substantially improved survival.

24. Cardiac Treatment

Cardiomyopathy may be treated with standard cardiac therapies.

These can include:

ACE inhibitors or ARBs.

Beta-blockers.

Mineralocorticoid-receptor antagonists in appropriate patients.

Early cardiac treatment is an important part of modern DMD care.

25. Prognosis

The older statement that patients generally die from respiratory or cardiac failure in their 20s or early 30s reflects historical experience.

With modern multidisciplinary care, many patients now survive well into adulthood, and survival continues to improve.

The major long-term threats remain:

Cardiomyopathy.

Respiratory failure.

But both can now be monitored and treated much more effectively than in the past.

26. Duchenne Muscular Dystrophy – Note Form

Inheritance: X-linked recessive.

Gene: DMD gene.

Protein abnormality: functional dystrophin essentially absent.

Onset: early childhood.

Weakness: progressive proximal pelvic- and shoulder-girdle weakness.

Gait: waddling gait.

Gowers sign: uses hands to climb up the legs when standing from the floor.

Calves: pseudohypertrophy due to fat and connective-tissue replacement.

CK: markedly raised.

Mobility: walking ability is progressively lost, historically around early adolescence, but modern treatment may prolong ambulation.

Respiratory complication: progressive respiratory muscle weakness and respiratory failure.

Cardiac complication: dilated cardiomyopathy and arrhythmias.

Diagnosis: high CK + DMD genetic testing.

Management: corticosteroids, physiotherapy, cardiac surveillance, respiratory support, genetic counselling, and selected mutation-specific therapies.

Key Clinical Pattern

Remember DMD as:

Young boy + proximal muscle weakness + waddling gait + Gowers sign + calf pseudohypertrophy + very high CK.

The core molecular defect is:

X-linked DMD mutation → absent dystrophin.

The easiest comparison with Becker muscular dystrophy is:

Duchenne → absent dystrophin → early onset + severe disease.

Becker → some dystrophin remains → later onset + milder disease.

Medicine – Becker Muscular Dystrophy

Becker muscular dystrophy (BMD) is an inherited X-linked recessive muscular dystrophy caused by abnormalities in the dystrophin protein. It is closely related to Duchenne muscular dystrophy (DMD), but the dystrophin abnormality is usually less severe, so the disease presents later and progresses more slowly.

1. Inheritance

Becker muscular dystrophy is inherited in an X-linked recessive pattern.

Therefore, it mainly affects males, while females are usually carriers, although some female carriers can develop muscle weakness or cardiac involvement.

The abnormal gene is the DMD gene on the X chromosome, which encodes dystrophin.

2. Dystrophin Abnormality

Dystrophin is a structural protein that helps connect the muscle-cell cytoskeleton to the surrounding extracellular matrix.

It stabilises the muscle membrane during contraction.

In Becker muscular dystrophy, dystrophin is usually reduced in quantity or abnormal in structure, but some functional protein remains.

This is the major reason BMD is milder than Duchenne muscular dystrophy.

3. Comparison with Duchenne Muscular Dystrophy

The key molecular distinction is:

Duchenne muscular dystrophy → dystrophin is essentially absent or severely deficient.

Becker muscular dystrophy → dystrophin is present but reduced or abnormal.

Because Becker patients retain some functional dystrophin, muscle-cell damage progresses more slowly.

4. Later Age of Onset

Becker muscular dystrophy generally manifests later than Duchenne muscular dystrophy.

Symptoms may begin in later childhood, adolescence, or occasionally adulthood.

This contrasts with Duchenne muscular dystrophy, which usually becomes clinically apparent in early childhood.

5. Milder Clinical Course

BMD generally causes a milder and more slowly progressive muscular dystrophy than DMD.

Patients often remain independently ambulant for much longer.

However, severity varies considerably, and some patients can still develop major skeletal-muscle, respiratory, or cardiac complications.

6. Muscle Weakness

The typical pattern is progressive proximal muscle weakness, especially involving the pelvic girdle and lower limbs.

Patients may develop difficulty:

Running.

Climbing stairs.

Getting up from the floor.

Rising from a chair.

Walking long distances.

Weakness generally progresses more slowly than in DMD.

7. Gowers Sign

Patients with significant proximal lower-limb weakness may demonstrate Gowers sign.

When rising from the floor, the patient uses the hands to “climb up” the thighs because the hip and thigh muscles are weak.

Gowers sign is not specific to Becker muscular dystrophy, but it is characteristic of proximal muscular weakness.

8. Calf Pseudohypertrophy

Calf pseudohypertrophy may occur.

The calves appear enlarged, but the enlargement is partly due to replacement of muscle tissue by fat and connective tissue, rather than true increase in functional muscle mass.

This finding is seen in both Becker and Duchenne muscular dystrophy.

9. Serum Creatine Kinase

Serum creatine kinase (CK) is usually markedly elevated because damaged skeletal muscle releases CK into the bloodstream.

An elevated CK may be detected even before severe clinical weakness develops.

However, CK levels alone cannot distinguish Becker from Duchenne muscular dystrophy.

10. Cardiac Involvement

Cardiac disease is an important complication of Becker muscular dystrophy.

Patients may develop dilated cardiomyopathy and cardiac rhythm abnormalities.

Importantly, the severity of cardiac disease does not always parallel the severity of skeletal-muscle weakness.

Therefore, even relatively mobile patients may require regular cardiac surveillance.

11. Female Carriers and the Heart

Female carriers of dystrophin mutations can occasionally develop cardiomyopathy, even when skeletal-muscle symptoms are minimal or absent.

This is why carrier identification and appropriate cardiac monitoring can be clinically important.

12. Respiratory Involvement

Respiratory muscle weakness can develop as the disease progresses.

This may lead to:

Reduced respiratory reserve.

Sleep-related hypoventilation.

Recurrent respiratory infections.

Respiratory failure in advanced disease.

Respiratory involvement generally occurs later than in classic Duchenne muscular dystrophy.

13. Diagnosis

Diagnosis is primarily based on genetic testing of the DMD gene.

This can identify deletions, duplications, or other pathogenic variants affecting dystrophin production.

Genetic testing has largely reduced the need for muscle biopsy in straightforward cases.

14. Muscle Biopsy

If genetic testing is inconclusive, muscle biopsy may sometimes be useful.

Immunohistochemical or protein analysis can demonstrate dystrophin that is reduced in amount or abnormal in size.

This contrasts with DMD, where dystrophin is usually nearly or completely absent.

15. Management

Management is multidisciplinary and focuses on preserving mobility, preventing complications, and monitoring cardiac and respiratory function.

Care may involve:

Neurology.

Physiotherapy.

Cardiology.

Respiratory medicine.

Rehabilitation.

Genetic counselling.

16. Physiotherapy

Physiotherapy helps maintain:

Joint mobility.

Muscle function.

Posture.

Walking ability.

Stretching and contracture prevention are important as weakness progresses.

Excessive high-intensity exercise that causes muscle injury should generally be avoided.

17. Cardiac Management

Patients require periodic assessment of cardiac function.

This may include:

ECG.

Echocardiography.

Cardiac MRI when indicated.

Cardiomyopathy may be treated with standard heart-failure therapies such as ACE inhibitors or related agents and beta-blockers when appropriate.

18. Genetic Counselling

Because BMD is X-linked, genetic counselling is important for affected families.

Carrier testing can help identify female relatives who may have reproductive implications or require cardiac surveillance.

Prenatal or reproductive genetic options may also be discussed when appropriate.

19. Becker versus Duchenne – Note Form

Inheritance in both: X-linked recessive.

Gene in both: DMD gene.

Protein in both: dystrophin.

Duchenne: dystrophin essentially absent.

Becker: dystrophin reduced or structurally abnormal but partly functional.

Duchenne onset: early childhood.

Becker onset: later childhood, adolescence, or adulthood.

Duchenne course: more severe and rapidly progressive.

Becker course: milder and more slowly progressive.

Both may show: proximal weakness, Gowers sign, calf pseudohypertrophy, elevated CK and cardiomyopathy.

Key Clinical Pattern

Remember Becker muscular dystrophy as:

X-linked dystrophin disorder + later onset + milder progression than Duchenne.

The easiest distinction is:

Duchenne → little or no functional dystrophin.

Becker → some functional dystrophin remains.

Therefore:

More dystrophin → later presentation and milder disease.

Medicine – Myotonic Dystrophy

Myotonic dystrophy, also called dystrophia myotonica, is an inherited multisystem disorder characterised by myotonia, progressive muscle weakness and wasting, cataracts, endocrine abnormalities, cardiac conduction disease, and characteristic facial features.

It is usually inherited in an autosomal dominant pattern.

1. Inheritance

Myotonic dystrophy is classically autosomal dominant.

The commonest form, myotonic dystrophy type 1 (DM1), is caused by expansion of a CTG trinucleotide repeat in the DMPK gene.

The number of repeats can increase when passed from one generation to the next, producing anticipation.

Anticipation means that the disease may appear earlier and more severely in successive generations.

2. Myotonia

Myotonia means delayed relaxation of skeletal muscle after voluntary contraction.

For example, a patient may tightly grip an examiner’s hand but then have difficulty releasing it promptly.

Therefore:

Muscle contracts normally → relaxation is delayed.

This is one of the defining features of myotonic dystrophy.

3. Percussion Myotonia

Myotonia can also be demonstrated by percussion.

Tapping certain muscles, such as the thenar muscles, may produce a prolonged contraction before relaxation.

This is called percussion myotonia.

4. Myotonic Facies

Patients may develop a characteristic appearance known as myotonic facies.

This results from weakness and wasting of the facial and temporal muscles.

Typical features include:

Long, thin face.

Temporal wasting.

Hollowed cheeks.

Weak facial expression.

Ptosis.

The overall appearance may become quite distinctive in established disease.

5. Bilateral Ptosis

Bilateral ptosis is common because of weakness of the muscles that elevate the upper eyelids.

Unlike myasthenia gravis, the ptosis is generally more persistent and occurs alongside other characteristic muscular and systemic features.

6. Facial Muscle Weakness

Weakness of facial muscles may cause:

Reduced facial expression.

Difficulty closing the eyes tightly.

Weakness of smiling or whistling.

Difficulty with speech or swallowing in advanced disease.

Muscle wasting around the temples and jaw contributes to the characteristic facial appearance.

7. Frontal Balding

Premature frontal balding, especially in men, is a classic associated feature.

It is not caused simply by muscle weakness but forms part of the multisystem phenotype of the disorder.

Thus, an examination combination such as:

Myotonia + frontal balding + cataracts + distal weakness

should strongly suggest myotonic dystrophy.

8. Pattern of Muscle Weakness

Muscle weakness is usually progressive.

In classic DM1, weakness often begins predominantly in the distal muscles, particularly:

Hand muscles.

Forearm muscles.

Ankle dorsiflexors.

Over time, more proximal muscle groups may become affected.

9. Muscle Wasting

Progressive weakness is accompanied by muscle wasting.

Commonly affected regions include:

Distal limbs.

Facial muscles.

Temporal muscles.

Sternocleidomastoid muscles.

Advanced disease can therefore produce substantial functional impairment.

10. Cataracts

Cataracts are a classic extramuscular manifestation.

A characteristic appearance is the so-called Christmas-tree cataract, which contains brightly coloured, iridescent lens opacities.

Not every patient has this exact appearance, but early cataract formation is strongly associated with myotonic dystrophy.

11. Insulin Resistance

Patients may develop insulin resistance and other metabolic abnormalities.

This may lead to impaired glucose tolerance or diabetes mellitus.

Insulin resistance is part of the broader endocrine involvement seen in myotonic dystrophy.

12. Other Endocrine Features

Other endocrine and reproductive abnormalities may occur.

These can include:

Testicular atrophy.

Reduced fertility.

Hypogonadism.

Thyroid dysfunction in some patients.

The disorder therefore affects much more than skeletal muscle.

13. Cardiac Involvement

An important feature not included in the original note is cardiac conduction disease.

Patients may develop:

PR prolongation.

Bundle branch block.

Atrioventricular block.

Atrial or ventricular arrhythmias.

Because conduction abnormalities can cause syncope or sudden cardiac death, cardiac surveillance is an important part of management.

14. Respiratory Involvement

Respiratory muscles can also become weak.

In addition, patients may have impaired central respiratory drive or sleep-disordered breathing.

Consequences can include:

Nocturnal hypoventilation.

Sleep apnoea.

Daytime somnolence.

Respiratory failure in advanced disease.

15. Gastrointestinal Involvement

Smooth-muscle dysfunction may affect the gastrointestinal tract.

Patients may develop:

Dysphagia.

Gastro-oesophageal reflux.

Constipation.

Intestinal dysmotility.

These features reinforce the fact that myotonic dystrophy is a multisystem disorder, not simply a muscular disease.

16. Myotonic Dystrophy Type 1 and Type 2

There are two major forms.

Myotonic dystrophy type 1 (DM1) is the classic form and is associated with CTG repeat expansion in the DMPK gene.

DM1 more commonly produces distal weakness, facial weakness, myotonia, cataracts, and potentially congenital disease.

Myotonic dystrophy type 2 (DM2) is caused by a different repeat expansion and often produces more proximal muscle weakness and pain.

The phenotype can overlap considerably with DM1.

17. Congenital Myotonic Dystrophy

Severe DM1 can occasionally present at birth as congenital myotonic dystrophy.

Affected infants may have:

Severe hypotonia.

Respiratory weakness.

Feeding difficulties.

Delayed motor development.

Congenital disease is particularly associated with maternal transmission.

18. Diagnosis

Diagnosis is usually confirmed by genetic testing.

For DM1, testing identifies an expanded CTG repeat in the DMPK gene.

Electromyography may also show characteristic myotonic discharges.

These are often described as having a waxing-and-waning sound resembling a “dive bomber,” although this description is mainly an examination teaching aid.

19. Management

There is no universal curative treatment, so management is largely multidisciplinary and supportive.

Important areas include:

Physiotherapy and rehabilitation.

Cardiac monitoring.

Respiratory assessment.

Treatment of cataracts.

Management of endocrine abnormalities.

Genetic counselling.

20. Treatment of Myotonia

Myotonia does not always require drug treatment.

If it is functionally troublesome, medications such as mexiletine may be used under specialist supervision.

Treatment is aimed at improving muscle relaxation rather than reversing the underlying genetic disorder.

21. Cardiac Surveillance

Patients require regular assessment for conduction abnormalities.

This may include:

ECG.

Ambulatory rhythm monitoring when indicated.

Cardiology review.

Some patients eventually require a pacemaker or implantable cardiac device depending on the conduction disturbance and arrhythmia risk.

22. Cataract Management

Cataracts are treated in the usual way when they become visually significant.

This generally involves cataract extraction with intraocular lens implantation.

Because cataracts may occur relatively early, visual symptoms should be actively assessed.

23. Myotonic Dystrophy – Note Form

Inheritance: autosomal dominant.

Classic mutation: CTG repeat expansion in the DMPK gene in DM1.

Anticipation: disease may become earlier and more severe in successive generations.

Myotonia: delayed relaxation after muscle contraction.

Myotonic facies: long thin face, temporal wasting, facial weakness and ptosis.

Ptosis: usually bilateral.

Frontal balding: classic associated feature.

Muscle weakness: progressive and classically distal in DM1.

Muscle wasting: affects distal limbs, facial muscles, temporal muscles and sternocleidomastoids.

Cataracts: common; Christmas-tree cataracts are characteristic.

Metabolic feature: insulin resistance.

Cardiac complication: conduction defects and arrhythmias.

Respiratory complication: respiratory muscle weakness and sleep-related hypoventilation.

Diagnosis: genetic testing ± EMG showing myotonic discharges.

Key Clinical Pattern

Remember myotonic dystrophy as:

Autosomal dominant + myotonia + distal muscle weakness + frontal balding + bilateral ptosis + cataracts + insulin resistance.

The most characteristic examination clue is:

Patient grips strongly but cannot relax the hand promptly.

And the major systemic complication to remember is:

Myotonic dystrophy → cardiac conduction disease and arrhythmias.

Medicine – Myasthenia Gravis

Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction that produces fluctuating, fatigable weakness of voluntary skeletal muscle. Weakness typically becomes worse with repeated activity and improves after rest.

The disease commonly affects the ocular, bulbar, limb, and respiratory muscles, while sensation and tendon reflexes are usually preserved.

1. Pathophysiology

In most patients, the immune system produces antibodies directed against components of the postsynaptic membrane of the neuromuscular junction.

The commonest antibodies are directed against the nicotinic acetylcholine receptor (AChR).

These antibodies reduce effective neuromuscular transmission by decreasing the number and function of available acetylcholine receptors and damaging the postsynaptic membrane.

2. Neuromuscular Junction Mechanism

Normally, acetylcholine is released from the presynaptic motor nerve terminal and binds to acetylcholine receptors on the muscle membrane.

This generates an end-plate potential and triggers muscle contraction.

In myasthenia gravis:

AChR antibodies → fewer functional postsynaptic acetylcholine receptors → reduced neuromuscular transmission → fatigable muscle weakness.

With repeated activity, neuromuscular transmission becomes progressively less effective, explaining the characteristic fatigability.

3. Other Antibodies

Not all patients have acetylcholine-receptor antibodies.

Some have antibodies against other postsynaptic proteins, particularly:

MuSK – muscle-specific kinase.

LRP4 – low-density lipoprotein receptor-related protein 4.

Therefore, a negative acetylcholine-receptor antibody test does not completely exclude myasthenia gravis.

4. Fatigable Weakness

The hallmark of MG is fluctuating weakness that worsens with repeated activity and improves with rest.

Patients may feel relatively strong in the morning but become weaker later in the day or after repeatedly using the same muscle group.

This contrasts with Lambert–Eaton myasthenic syndrome, in which strength may temporarily improve after brief exercise.

5. Ptosis

Ptosis is one of the most common presenting features.

It may be unilateral or bilateral and often fluctuates.

A characteristic feature is that the ptosis may become more obvious when the patient is asked to maintain prolonged upward gaze.

After resting or closing the eyes, the ptosis may improve.

6. Ophthalmoplegia

Weakness of the extraocular muscles can produce:

Diplopia.

Variable ophthalmoplegia.

The pattern may change during examination because different ocular muscles fatigue at different rates.

Importantly, pupillary function is preserved in myasthenia gravis because the pupil is controlled by autonomic smooth muscle rather than skeletal muscle.

Thus:

Ptosis + ophthalmoplegia + normal pupils → consider myasthenia gravis.

7. Bulbar Weakness

Muscles involved in speech, swallowing, and facial movement may become affected.

Patients may develop:

Dysarthria.

Dysphagia.

Nasal speech.

Difficulty chewing.

Facial weakness.

Speech may become progressively weaker or more nasal after prolonged talking.

8. Limb Weakness

Limb involvement generally produces proximal greater than distal weakness.

Patients may have difficulty:

Climbing stairs.

Getting up from a chair.

Lifting objects above the head.

Combing their hair.

The weakness fluctuates and becomes more pronounced after repeated muscular activity.

9. Sensation and Reflexes

Sensation is normally intact in myasthenia gravis.

Deep tendon reflexes are also generally preserved.

This is useful when distinguishing MG from conditions such as Lambert–Eaton syndrome, where tendon reflexes are commonly reduced.

10. Respiratory Muscle Weakness

Respiratory muscle involvement is potentially life-threatening.

Weakness of the diaphragm and other respiratory muscles can cause ventilatory failure.

Severe respiratory weakness in a patient with myasthenia gravis is known as a myasthenic crisis.

This requires urgent assessment and often intensive respiratory monitoring.

11. Myasthenic Crisis

A myasthenic crisis is severe worsening of MG resulting in respiratory insufficiency and/or severe bulbar weakness.

Common triggers include:

Infection.

Surgery.

Medication changes.

Pregnancy or physiological stress.

Certain drugs that impair neuromuscular transmission.

Patients may require ventilatory support and specialist treatment with intravenous immunoglobulin or plasma exchange.

12. Acetylcholine-Receptor Antibodies

Blood testing for AChR antibodies is an important diagnostic investigation.

The old figure of approximately 90% needs qualification.

AChR antibodies are found in the great majority of patients with generalised MG, but sensitivity is lower in purely ocular disease.

Therefore:

Positive AChR antibodies strongly support the diagnosis, but negative antibodies do not exclude MG.

13. MuSK Antibodies

Patients who are negative for AChR antibodies may be tested for MuSK antibodies.

MuSK-positive MG can particularly involve:

Bulbar muscles.

Facial muscles.

Neck muscles.

Respiratory muscles.

The clinical phenotype and treatment response can differ somewhat from classic AChR-positive disease.

14. Electromyography

Electrophysiological testing assesses the reliability of neuromuscular transmission.

With repetitive nerve stimulation, patients with MG typically show a decremental response in the compound muscle action potential.

In simple terms:

Repeated stimulation → progressively smaller muscle response.

This reflects failure of neuromuscular transmission.

15. Single-Fibre EMG

Single-fibre electromyography is particularly sensitive for detecting impaired neuromuscular transmission.

It demonstrates increased variability in the timing of muscle-fibre activation, called increased jitter.

It is useful when routine investigations are inconclusive but clinical suspicion remains high.

16. Edrophonium – Tensilon Test

Historically, the Tensilon test used intravenous edrophonium, a very short-acting acetylcholinesterase inhibitor.

By inhibiting acetylcholinesterase, edrophonium temporarily increased acetylcholine at the neuromuscular junction.

A patient with MG could therefore show rapid temporary improvement in weakness.

The mechanism was:

Edrophonium → acetylcholinesterase inhibition → ↑ acetylcholine → improved neuromuscular transmission → temporary improvement in weakness.

17. Tensilon Test in Modern Practice

The Tensilon test is now largely historical and is not routinely used in many modern clinical settings because edrophonium can cause significant adverse effects, including bradycardia and other cardiovascular complications.

Modern diagnosis relies more heavily on:

Antibody testing.

Repetitive nerve stimulation.

Single-fibre EMG.

Clinical bedside assessment remains important.

18. Ice-Pack Test

For patients with prominent ptosis, the ice-pack test can provide useful bedside evidence.

An ice pack is placed over the closed eyelid for a few minutes.

Improvement in ptosis after cooling supports a diagnosis of myasthenia gravis because lower temperatures can improve neuromuscular transmission.

It is particularly useful in ocular MG.

19. Thymus Association

Myasthenia gravis has an important relationship with the thymus gland.

Patients may have:

Thymic hyperplasia.

or

Thymoma.

The thymus is believed to play an important role in generating the abnormal autoimmune response in many patients with AChR-positive MG.

20. CT Thorax

Patients with newly diagnosed MG are generally evaluated for a thymoma, commonly using CT imaging of the chest.

Therefore:

Myasthenia gravis → image the mediastinum to exclude thymoma.

This association is particularly important for examinations.

21. Pyridostigmine

Pyridostigmine is a commonly used symptomatic treatment.

It is an acetylcholinesterase inhibitor.

By reducing the breakdown of acetylcholine, it increases the amount of acetylcholine available at the neuromuscular junction.

The mechanism is:

Acetylcholinesterase inhibition → ↑ acetylcholine in synaptic cleft → improved activation of remaining ACh receptors → improved strength.

22. Limitations of Pyridostigmine

Pyridostigmine improves symptoms but does not remove the underlying autoimmune process.

Adverse effects arise mainly from excess cholinergic activity and may include:

Abdominal cramps.

Diarrhoea.

Increased salivation.

Sweating.

Muscle fasciculations in excessive doses.

23. Corticosteroids

Corticosteroids, such as prednisolone, are frequently used when symptomatic therapy alone is insufficient.

They suppress the autoimmune response and can substantially improve muscle strength.

Because steroids can occasionally cause transient worsening when first introduced, initiation and dose escalation may require careful specialist supervision in patients with significant bulbar or respiratory involvement.

24. Other Immunosuppressive Treatments

Additional steroid-sparing immunosuppressive drugs may be used for long-term disease control.

Examples include:

Azathioprine.

Mycophenolate mofetil.

Other immunotherapies, including targeted biologic agents, are increasingly used for selected patients with refractory or severe disease.

25. Thymectomy

Thymectomy is indicated when a thymoma is present, provided the patient is an appropriate surgical candidate.

Thymectomy can also improve outcomes in selected patients with generalised AChR-antibody-positive MG even without thymoma.

Therefore, thymectomy is not simply a treatment for thymoma; in appropriately selected patients it can modify the course of autoimmune MG itself.

26. Plasma Exchange

Plasma exchange removes circulating pathogenic antibodies and can produce relatively rapid improvement.

It is particularly useful in:

Myasthenic crisis.

Severe exacerbations.

Preparation for surgery in selected high-risk patients.

Its effects occur rapidly but are relatively short-lived.

27. Intravenous Immunoglobulin

Intravenous immunoglobulin (IVIG) is another rapid immunomodulatory treatment.

It is commonly used for:

Myasthenic crisis.

Severe exacerbations.

Situations where rapid improvement is required.

Like plasma exchange, it is primarily used for relatively rapid short-term disease control rather than routine symptomatic therapy.

28. Drugs That Can Worsen Myasthenia

Certain medications can impair neuromuscular transmission and worsen MG.

Important examples include some:

Aminoglycoside antibiotics.

Fluoroquinolones.

Macrolides.

Magnesium-containing preparations.

Beta-blockers.

Neuromuscular-blocking drugs used during anaesthesia.

Medication decisions depend on clinical circumstances, but patients with MG should have potentially aggravating drugs reviewed carefully.

29. Myasthenia Gravis versus Lambert–Eaton Syndrome

Myasthenia gravis:

Postsynaptic disorder.

Usually antibodies against ACh receptors.

Weakness worsens with repeated activity.

Ocular symptoms are common.

Reflexes generally preserved.

Autonomic symptoms are uncommon.

Associated with thymic hyperplasia or thymoma.

Lambert–Eaton syndrome:

Presynaptic disorder.

Antibodies against voltage-gated calcium channels.

Weakness may improve temporarily with brief exercise.

Proximal lower-limb weakness is prominent.

Reflexes reduced.

Autonomic symptoms common.

Strongly associated with small-cell lung carcinoma.

30. Myasthenia Gravis – Note Form

Definition: autoimmune neuromuscular-junction disorder causing fluctuating, fatigable skeletal-muscle weakness.

Main antibody: postsynaptic acetylcholine-receptor antibody.

Other antibodies: MuSK and LRP4.

Ptosis: common, fluctuating and worsens with prolonged upward gaze.

Ophthalmoplegia: causes diplopia; pupils remain normal.

Bulbar involvement: dysarthria, dysphagia, nasal speech and chewing fatigue.

Weakness: worsens with repeated activity and improves with rest.

Sensation: normal.

Reflexes: usually normal.

Respiratory involvement: can cause life-threatening myasthenic crisis.

Antibody testing: AChR antibodies are highly useful, particularly in generalised MG.

EMG: decremental response with repetitive nerve stimulation.

Single-fibre EMG: increased jitter and high sensitivity.

Tensilon test: historical edrophonium test; rapid improvement occurred after short-acting acetylcholinesterase inhibition, but it is now rarely used.

Thoracic imaging: performed to look for thymoma.

Symptomatic treatment: pyridostigmine.

Immunotherapy: corticosteroids and other immunosuppressive treatments.

Thymectomy: mandatory consideration with thymoma and beneficial in selected generalised AChR-positive patients without thymoma.

Severe exacerbation/crisis: IVIG or plasma exchange ± ventilatory support.

Key Clinical Pattern

Remember myasthenia gravis as:

Ptosis + diplopia + bulbar weakness + fatigable skeletal-muscle weakness that worsens with repeated activity.

The neurological examination typically shows:

Weak muscles + normal sensation + preserved reflexes + normal pupils.

The core mechanism is:

Postsynaptic ACh-receptor antibodies → impaired neuromuscular transmission.

The key association is:

Myasthenia gravis → thymoma/thymic abnormalities.

And the easiest comparison remains:

MG → weakness worsens with activity.

LEMS → weakness initially improves with activity.

1. Pathophysiology In most patients, the immune system produces antibodies directed against components of the postsynaptic membrane of the neuromuscular junction. The commonest antibodies are directed against the nicotinic acetylcholine receptor (AChR). These antibodies reduce effective neuromuscular transmission by decreasing the number and function of available acetylcholine receptors and damaging the postsynaptic membrane. 

2. Neuromuscular Junction Mechanism Normally, acetylcholine is released from the presynaptic motor nerve terminal and binds to acetylcholine receptors on the muscle membrane. This generates an end-plate potential and triggers muscle contraction. In myasthenia gravis: AChR antibodies → fewer functional postsynaptic acetylcholine receptors → reduced neuromuscular transmission → fatigable muscle weakness. With repeated activity, neuromuscular transmission becomes progressively less effective, explaining the characteristic fatigability. 

3. Other Antibodies Not all patients have acetylcholine-receptor antibodies. Some have antibodies against other postsynaptic proteins, particularly: MuSK – muscle-specific kinase. LRP4 – low-density lipoprotein receptor-related protein 4. Therefore, a negative acetylcholine-receptor antibody test does not completely exclude myasthenia gravis. 

4. Fatigable Weakness The hallmark of MG is fluctuating weakness that worsens with repeated activity and improves with rest. Patients may feel relatively strong in the morning but become weaker later in the day or after repeatedly using the same muscle group. This contrasts with Lambert–Eaton myasthenic syndrome, in which strength may temporarily improve after brief exercise. 

5. Ptosis Ptosis is one of the most common presenting features. It may be unilateral or bilateral and often fluctuates. A characteristic feature is that the ptosis may become more obvious when the patient is asked to maintain prolonged upward gaze. After resting or closing the eyes, the ptosis may improve. 

6. Ophthalmoplegia Weakness of the extraocular muscles can produce: Diplopia. Variable ophthalmoplegia. The pattern may change during examination because different ocular muscles fatigue at different rates. Importantly, pupillary function is preserved in myasthenia gravis because the pupil is controlled by autonomic smooth muscle rather than skeletal muscle. Thus: Ptosis + ophthalmoplegia + normal pupils → consider myasthenia gravis. 

7. Bulbar Weakness Muscles involved in speech, swallowing, and facial movement may become affected. Patients may develop: Dysarthria. Dysphagia. Nasal speech. Difficulty chewing. Facial weakness. Speech may become progressively weaker or more nasal after prolonged talking. 

8. Limb Weakness Limb involvement generally produces proximal greater than distal weakness. Patients may have difficulty: Climbing stairs. Getting up from a chair. Lifting objects above the head. Combing their hair. The weakness fluctuates and becomes more pronounced after repeated muscular activity. 

9. Sensation and Reflexes Sensation is normally intact in myasthenia gravis. Deep tendon reflexes are also generally preserved. This is useful when distinguishing MG from conditions such as Lambert–Eaton syndrome, where tendon reflexes are commonly reduced. 

10. Respiratory Muscle Weakness Respiratory muscle involvement is potentially life-threatening. Weakness of the diaphragm and other respiratory muscles can cause ventilatory failure. Severe respiratory weakness in a patient with myasthenia gravis is known as a myasthenic crisis. This requires urgent assessment and often intensive respiratory monitoring. 

11. Myasthenic Crisis A myasthenic crisis is severe worsening of MG resulting in respiratory insufficiency and/or severe bulbar weakness. Common triggers include: Infection. Surgery. Medication changes. Pregnancy or physiological stress. Certain drugs that impair neuromuscular transmission. Patients may require ventilatory support and specialist treatment with intravenous immunoglobulin or plasma exchange. 

12. Acetylcholine-Receptor Antibodies Blood testing for AChR antibodies is an important diagnostic investigation. The old figure of approximately 90% needs qualification. AChR antibodies are found in the great majority of patients with generalised MG, but sensitivity is lower in purely ocular disease. Therefore: Positive AChR antibodies strongly support the diagnosis, but negative antibodies do not exclude MG. 

13. MuSK Antibodies Patients who are negative for AChR antibodies may be tested for MuSK antibodies. MuSK-positive MG can particularly involve: Bulbar muscles. Facial muscles. Neck muscles. Respiratory muscles. The clinical phenotype and treatment response can differ somewhat from classic AChR-positive disease. 

14. Electromyography Electrophysiological testing assesses the reliability of neuromuscular transmission. With repetitive nerve stimulation, patients with MG typically show a decremental response in the compound muscle action potential. In simple terms: Repeated stimulation → progressively smaller muscle response. This reflects failure of neuromuscular transmission. 

15. Single-Fibre EMG Single-fibre electromyography is particularly sensitive for detecting impaired neuromuscular transmission. It demonstrates increased variability in the timing of muscle-fibre activation, called increased jitter. It is useful when routine investigations are inconclusive but clinical suspicion remains high. 

16. Edrophonium – Tensilon Test Historically, the Tensilon test used intravenous edrophonium, a very short-acting acetylcholinesterase inhibitor. By inhibiting acetylcholinesterase, edrophonium temporarily increased acetylcholine at the neuromuscular junction. A patient with MG could therefore show rapid temporary improvement in weakness. The mechanism was: Edrophonium → acetylcholinesterase inhibition → ↑ acetylcholine → improved neuromuscular transmission → temporary improvement in weakness. 

17. Tensilon Test in Modern Practice The Tensilon test is now largely historical and is not routinely used in many modern clinical settings because edrophonium can cause significant adverse effects, including bradycardia and other cardiovascular complications. Modern diagnosis relies more heavily on: Antibody testing. Repetitive nerve stimulation. Single-fibre EMG. Clinical bedside assessment remains important. 

18. Ice-Pack Test For patients with prominent ptosis, the ice-pack test can provide useful bedside evidence. An ice pack is placed over the closed eyelid for a few minutes. Improvement in ptosis after cooling supports a diagnosis of myasthenia gravis because lower temperatures can improve neuromuscular transmission. It is particularly useful in ocular MG. 

19. Thymus Association Myasthenia gravis has an important relationship with the thymus gland. Patients may have: Thymic hyperplasia. or Thymoma. The thymus is believed to play an important role in generating the abnormal autoimmune response in many patients with AChR-positive MG. 

20. CT Thorax Patients with newly diagnosed MG are generally evaluated for a thymoma, commonly using CT imaging of the chest. Therefore: Myasthenia gravis → image the mediastinum to exclude thymoma. This association is particularly important for examinations. 

21. Pyridostigmine Pyridostigmine is a commonly used symptomatic treatment. It is an acetylcholinesterase inhibitor. By reducing the breakdown of acetylcholine, it increases the amount of acetylcholine available at the neuromuscular junction. The mechanism is: Acetylcholinesterase inhibition → ↑ acetylcholine in synaptic cleft → improved activation of remaining ACh receptors → improved strength. 

22. Limitations of Pyridostigmine Pyridostigmine improves symptoms but does not remove the underlying autoimmune process. Adverse effects arise mainly from excess cholinergic activity and may include: Abdominal cramps. Diarrhoea. Increased salivation. Sweating. Muscle fasciculations in excessive doses. 

23. Corticosteroids Corticosteroids, such as prednisolone, are frequently used when symptomatic therapy alone is insufficient. They suppress the autoimmune response and can substantially improve muscle strength. Because steroids can occasionally cause transient worsening when first introduced, initiation and dose escalation may require careful specialist supervision in patients with significant bulbar or respiratory involvement. 

24. Other Immunosuppressive Treatments Additional steroid-sparing immunosuppressive drugs may be used for long-term disease control. Examples include: Azathioprine. Mycophenolate mofetil. Other immunotherapies, including targeted biologic agents, are increasingly used for selected patients with refractory or severe disease. 

25. Thymectomy Thymectomy is indicated when a thymoma is present, provided the patient is an appropriate surgical candidate. Thymectomy can also improve outcomes in selected patients with generalised AChR-antibody-positive MG even without thymoma. Therefore, thymectomy is not simply a treatment for thymoma; in appropriately selected patients it can modify the course of autoimmune MG itself. 

26. Plasma Exchange Plasma exchange removes circulating pathogenic antibodies and can produce relatively rapid improvement. It is particularly useful in: Myasthenic crisis. Severe exacerbations. Preparation for surgery in selected high-risk patients. Its effects occur rapidly but are relatively short-lived. 

27. Intravenous Immunoglobulin Intravenous immunoglobulin (IVIG) is another rapid immunomodulatory treatment. It is commonly used for: Myasthenic crisis. Severe exacerbations. Situations where rapid improvement is required. Like plasma exchange, it is primarily used for relatively rapid short-term disease control rather than routine symptomatic therapy. 

28. Drugs That Can Worsen Myasthenia Certain medications can impair neuromuscular transmission and worsen MG. Important examples include some: Aminoglycoside antibiotics. Fluoroquinolones. Macrolides. Magnesium-containing preparations. Beta-blockers. Neuromuscular-blocking drugs used during anaesthesia. Medication decisions depend on clinical circumstances, but patients with MG should have potentially aggravating drugs reviewed carefully. 

29. Myasthenia Gravis versus Lambert–Eaton Syndrome Myasthenia gravis: Postsynaptic disorder. Usually antibodies against ACh receptors. Weakness worsens with repeated activity. Ocular symptoms are common. Reflexes generally preserved. Autonomic symptoms are uncommon. Associated with thymic hyperplasia or thymoma. 

Lambert–Eaton syndrome: Presynaptic disorder. Antibodies against voltage-gated calcium channels. Weakness may improve temporarily with brief exercise. Proximal lower-limb weakness is prominent. Reflexes reduced. Autonomic symptoms common. Strongly associated with small-cell lung carcinoma. 

30. Myasthenia Gravis – Note Form Definition: autoimmune neuromuscular-junction disorder causing fluctuating, fatigable skeletal-muscle weakness. 

Main antibody: postsynaptic acetylcholine-receptor antibody. 

Other antibodies: MuSK and LRP4. 

Ptosis: common, fluctuating and worsens with prolonged upward gaze. 

Ophthalmoplegia: causes diplopia; pupils remain normal. 

Bulbar involvement: dysarthria, dysphagia, nasal speech and chewing fatigue. 

Weakness: worsens with repeated activity and improves with rest. 

Sensation: normal. 

Reflexes: usually normal. 

Respiratory involvement: can cause life-threatening myasthenic crisis. 

Antibody testing: AChR antibodies are highly useful, particularly in generalised MG. 

EMG: decremental response with repetitive nerve stimulation. 

Single-fibre EMG: increased jitter and high sensitivity. 

Tensilon test: historical edrophonium test; rapid improvement occurred after short-acting acetylcholinesterase inhibition, but it is now rarely used. 

Thoracic imaging: performed to look for thymoma. 

Symptomatic treatment: pyridostigmine. 

Immunotherapy: corticosteroids and other immunosuppressive treatments. 

Thymectomy: mandatory consideration with thymoma and beneficial in selected generalised AChR-positive patients without thymoma. 

Severe exacerbation/crisis: IVIG or plasma exchange ± ventilatory support. 

Key Clinical Pattern Remember myasthenia gravis as: Ptosis + diplopia + bulbar weakness + fatigable skeletal-muscle weakness that worsens with repeated activity. The neurological examination typically shows: Weak muscles + normal sensation + preserved reflexes + normal pupils. The core mechanism is: Postsynaptic ACh-receptor antibodies → impaired neuromuscular transmission. The key association is: Myasthenia gravis → thymoma/thymic abnormalities. And the easiest comparison remains: MG → weakness worsens with activity. LEMS → weakness initially improves with activity.

Medicine – Lambert–Eaton Myasthenic Syndrome

Lambert–Eaton myasthenic syndrome (LEMS) is an autoimmune disorder of the presynaptic neuromuscular junction. It causes impaired release of acetylcholine from motor nerve terminals and therefore produces characteristic muscle weakness.

It is especially important because it may occur as a paraneoplastic syndrome, classically in association with small-cell lung carcinoma.

1. Autoimmune Mechanism

In LEMS, autoantibodies are directed mainly against presynaptic P/Q-type voltage-gated calcium channels on the motor nerve terminal.

Normally, when a nerve impulse reaches the presynaptic terminal, voltage-gated calcium channels open and allow calcium to enter.

The calcium influx then triggers release of acetylcholine into the neuromuscular junction.

2. Effect of Calcium-Channel Antibodies

When these calcium channels are impaired by autoantibodies, less calcium enters the nerve terminal.

This causes reduced acetylcholine release.

The sequence is:

Antibodies against presynaptic Ca²⁺ channels → reduced Ca²⁺ entry → reduced acetylcholine release → impaired neuromuscular transmission → muscle weakness.

3. Paraneoplastic Association

LEMS has a particularly strong association with small-cell lung carcinoma (SCLC).

Small-cell carcinoma can express proteins resembling neuronal voltage-gated calcium channels.

The immune response directed against the tumour can therefore cross-react with calcium channels at the neuromuscular junction.

This produces a classic paraneoplastic neurological syndrome.

4. Non-Paraneoplastic LEMS

Not every patient with LEMS has cancer.

Some cases are purely autoimmune and may occur without an underlying malignancy.

However, because of the strong association with SCLC, patients with newly diagnosed LEMS generally require appropriate assessment for an underlying malignancy, particularly lung cancer.

5. Proximal Muscle Weakness

The characteristic weakness is predominantly proximal rather than distal.

The lower limbs are often affected first and most severely.

Patients may therefore complain of difficulty:

Rising from a chair.

Climbing stairs.

Getting out of bed.

Walking for prolonged periods.

Upper-limb proximal weakness may develop later.

6. Lower Limb Predominance

LEMS commonly affects the pelvic-girdle and thigh muscles before the upper limbs.

Patients may initially describe their legs as heavy or weak.

This lower-limb proximal pattern is an important clue when distinguishing LEMS from some other neuromuscular-junction disorders.

7. Facilitation with Exercise

A very characteristic feature of LEMS is that muscle strength may temporarily improve after brief exercise.

This is called facilitation or post-exercise improvement.

Repeated nerve activity allows calcium to accumulate within the presynaptic nerve terminal.

Even though calcium-channel function is reduced, the accumulated calcium allows more acetylcholine to be released.

Therefore:

Brief exercise → increased presynaptic Ca²⁺ accumulation → increased acetylcholine release → temporary improvement in strength.

8. Weakness with Sustained Activity

The original note states that weakness improves with exercise and then weakens again with sustained exercise.

This is a useful general concept.

The most characteristic finding is initial facilitation after brief activity. With prolonged or repeated exertion, the improvement may not persist, and fatigue can again become apparent.

Therefore, remember:

LEMS → brief exercise improves strength.

This contrasts with the classic fatigability of myasthenia gravis.

9. Reduced Reflexes

An important feature not included in the original notes is reduced or absent tendon reflexes.

Patients often have hyporeflexia or areflexia.

However, reflexes may temporarily improve after the patient contracts the relevant muscle for several seconds.

This phenomenon is another example of post-activation facilitation.

10. Autonomic Symptoms

LEMS frequently affects the autonomic nervous system because voltage-gated calcium channels also participate in autonomic neurotransmission.

Common autonomic symptoms include:

Dry mouth.

Constipation.

Erectile dysfunction.

Reduced sweating.

Orthostatic symptoms.

Dry mouth is particularly common.

11. Ocular and Bulbar Symptoms

Ocular symptoms such as ptosis and diplopia can occur, but they are usually less prominent than in myasthenia gravis.

Bulbar symptoms such as dysarthria or dysphagia may also occur but are generally less dominant.

This helps distinguish the typical clinical patterns of the two diseases.

12. LEMS versus Myasthenia Gravis

The two disorders both affect neuromuscular transmission but at different sites.

LEMS is presynaptic.

The autoantibodies attack voltage-gated calcium channels, reducing acetylcholine release.

Myasthenia gravis is mainly postsynaptic.

The immune system commonly attacks acetylcholine receptors or related postsynaptic proteins, impairing the muscle’s response to released acetylcholine.

13. Pattern of Weakness

In LEMS:

Proximal lower-limb weakness predominates.

Strength may initially improve with brief exercise.

Reflexes are often reduced.

Autonomic symptoms are common.

In myasthenia gravis:

Ocular and bulbar weakness are common.

Weakness generally worsens with repeated activity and improves with rest.

Reflexes are usually preserved.

Autonomic symptoms are not characteristic.

14. Electrophysiology

Nerve-conduction studies and repetitive nerve stimulation can support the diagnosis.

At rest, the compound muscle action potential may be reduced.

After brief exercise or high-frequency stimulation, there can be a marked increment in response amplitude.

This electrophysiological facilitation reflects increased acetylcholine release after repeated presynaptic stimulation.

15. Antibody Testing

Blood testing may detect antibodies against P/Q-type voltage-gated calcium channels.

A positive result supports the diagnosis when the clinical pattern is compatible.

However, diagnosis still depends on integrating symptoms, examination, electrophysiology, antibody results, and assessment for an underlying malignancy.

16. Investigation for Small-Cell Lung Cancer

Because LEMS may precede recognition of SCLC, patients should be evaluated for an underlying lung malignancy when clinically appropriate.

This may involve thoracic imaging and sometimes repeated surveillance if initial assessment is negative but clinical suspicion remains significant.

17. Treatment of the Underlying Tumour

When LEMS is associated with small-cell lung carcinoma, treating the malignancy is a crucial part of management.

Improvement in tumour control may also improve the neurological syndrome.

18. Amifampridine

A major symptomatic treatment for LEMS is amifampridine (3,4-diaminopyridine).

It blocks presynaptic potassium channels and prolongs depolarisation of the motor nerve terminal.

This allows more calcium to enter and increases acetylcholine release.

The sequence is:

K⁺ channel blockade → prolonged depolarisation → ↑ Ca²⁺ entry → ↑ acetylcholine release → improved muscle strength.

19. Other Treatment

Selected patients may require additional treatment such as pyridostigmine, although its benefit is usually less striking than in myasthenia gravis.

Immunomodulatory treatments may also be used in autoimmune disease, including corticosteroid-sparing therapy, intravenous immunoglobulin, or other specialist-directed therapy depending on severity.

20. Lambert–Eaton Syndrome – Note Form

Definition: autoimmune presynaptic neuromuscular-junction disorder.

Antibody target: P/Q-type voltage-gated calcium channels on the presynaptic motor nerve terminal.

Mechanism: reduced calcium entry → reduced acetylcholine release.

Classic malignancy: small-cell lung carcinoma.

Weakness: predominantly proximal.

Distribution: lower limbs usually affected more than upper limbs.

Exercise: strength characteristically improves temporarily after brief exercise.

Reflexes: reduced or absent but may improve after muscle activation.

Autonomic symptoms: dry mouth, constipation, erectile dysfunction, impaired sweating and orthostatic symptoms.

Ocular symptoms: can occur but are usually less prominent than in myasthenia gravis.

Electrophysiology: incremental response after exercise or high-frequency stimulation.

Treatment: treat underlying malignancy when present; amifampridine is an important symptomatic therapy.

Key Clinical Pattern

Remember LEMS as:

Proximal lower-limb weakness + reduced reflexes + autonomic symptoms + strength improves with brief exercise.

The mechanism is:

Presynaptic voltage-gated Ca²⁺ channel antibodies → ↓ acetylcholine release.

The classic association is:

Lambert–Eaton syndrome → small-cell lung carcinoma.

And the easiest comparison is:

LEMS → gets stronger initially with exercise + reflexes reduced + autonomic symptoms common.

Myasthenia gravis → gets weaker with repeated activity + reflexes preserved + ocular symptoms prominent.

Medicine – Multiple Sclerosis

Multiple sclerosis (MS) is a chronic immune-mediated inflammatory demyelinating disease of the central nervous system (CNS). It affects the brain, spinal cord, and optic nerves and is characterised by episodes of neurological dysfunction caused by inflammation, demyelination, and eventually varying degrees of axonal loss.

A central diagnostic concept is that lesions are disseminated in space and time—that is, they occur in different parts of the CNS and at different points in time.

1. Pathophysiology

MS is primarily an immune-mediated disease directed against components of CNS myelin and related neural tissue.

Both T-cell and B-cell immune mechanisms are involved.

Inflammatory cells cross the blood–brain barrier and contribute to:

Demyelination.

Oligodendrocyte injury.

Axonal damage.

Formation of plaques within CNS white matter and other regions.

Over time, repeated inflammatory injury can lead to irreversible neurodegeneration and disability.

2. Dissemination in Space and Time

The phrase “disseminated in time and place” is better expressed as:

Dissemination in space + dissemination in time.

Dissemination in space means lesions are found in different characteristic CNS locations.

Dissemination in time means there is evidence that lesions developed at different times.

This principle is central to modern MS diagnosis.

3. Typical Sites of Lesions

MS lesions commonly occur in areas such as:

Periventricular white matter.

Juxtacortical or cortical regions.

Infratentorial structures.

Spinal cord.

Optic nerves.

These locations help distinguish MS from many other white-matter disorders.

4. Clinical Presentation

MS can present in many different ways because lesions can occur throughout the CNS.

The percentages in older notes vary widely between studies, so they are best treated as historical approximations rather than fixed frequencies.

Common presenting symptoms include:

Weakness.

Optic neuritis.

Paraesthesiae or sensory disturbance.

Diplopia.

Bladder dysfunction.

Vertigo or imbalance.

5. Weakness

Patients may develop weakness affecting one or more limbs.

Because MS involves the CNS, weakness often has upper motor neurone features, such as:

Spasticity.

Hyperreflexia.

Extensor plantar responses.

Weakness may be focal, asymmetric, or involve both legs depending on lesion location.

6. Optic Neuritis

Optic neuritis is a classic presentation of MS.

Patients typically develop:

Subacute unilateral visual loss.

Pain on eye movement.

Reduced colour saturation, especially red.

Central scotoma.

Relative afferent pupillary defect.

The optic disc may appear normal initially if the inflammation is retrobulbar.

7. Sensory Symptoms

Paraesthesiae are common.

Patients may describe:

Pins and needles.

Numbness.

Burning sensations.

Tingling.

Electric-shock sensations.

A particularly characteristic symptom is Lhermitte phenomenon, in which flexion of the neck produces an electric-shock-like sensation down the spine or limbs due to cervical cord involvement.

8. Diplopia

Diplopia may occur because MS commonly affects brainstem pathways controlling eye movements.

One classic finding is internuclear ophthalmoplegia (INO) caused by involvement of the medial longitudinal fasciculus.

This produces impaired adduction of one eye with nystagmus of the abducting eye.

Bilateral INO in a young adult is strongly suggestive of MS.

9. Bladder Dysfunction

Bladder symptoms may occur due to spinal cord or supraspinal involvement.

Patients may develop:

Urgency.

Frequency.

Urge incontinence.

Difficulty emptying the bladder.

Retention in more advanced disease.

The original 5% figure should not be treated as universal because bladder dysfunction becomes common during the course of established MS.

10. Vertigo and Balance Problems

Brainstem and cerebellar lesions can cause:

Vertigo.

Ataxia.

Tremor.

Dysarthria.

Nystagmus.

Balance disturbance may significantly impair mobility even when limb strength is relatively preserved.

11. Other Important Symptoms

MS may also cause:

Fatigue.

Cognitive dysfunction.

Spasticity.

Neuropathic pain.

Sexual dysfunction.

Bowel dysfunction.

Mood disturbance.

Heat sensitivity.

Symptoms can fluctuate and may worsen temporarily with fever or increased body temperature.

12. Uhthoff Phenomenon

Uhthoff phenomenon refers to temporary worsening of previous neurological symptoms when body temperature rises.

This may occur with:

Exercise.

Hot weather.

Fever.

Hot baths.

It reflects impaired conduction through previously demyelinated nerve fibres rather than formation of a new lesion.

13. Relapsing-Remitting MS

The most common initial disease pattern is relapsing-remitting MS (RRMS).

Patients experience episodes of new or worsening neurological symptoms called relapses, followed by partial or complete recovery.

Relapses usually develop over hours to days and persist for at least 24 hours in the absence of fever or infection.

14. Secondary Progressive MS

Some patients with relapsing-remitting disease later develop secondary progressive MS (SPMS).

This is characterised by gradual worsening of neurological disability independent of clearly defined relapses.

Modern disease-modifying treatment aims partly to reduce the chance or delay the development of progressive disability.

15. Primary Progressive MS

A further important category is primary progressive MS (PPMS).

In this form, disability gradually worsens from the beginning without a typical initial relapsing-remitting pattern.

Patients often present with progressive spinal cord symptoms, particularly worsening gait and lower-limb stiffness.

16. MRI

MRI is the most important imaging investigation in suspected MS.

Typical lesions appear as areas of high signal intensity on T2-weighted and FLAIR sequences.

Characteristic distributions include:

Periventricular lesions.

Juxtacortical/cortical lesions.

Infratentorial lesions.

Spinal cord lesions.

17. Gadolinium Enhancement

Active inflammatory lesions may enhance after administration of gadolinium contrast.

The simultaneous presence of enhancing and non-enhancing lesions can provide evidence of lesions of different ages and therefore support dissemination in time.

Serial MRI can also demonstrate new lesions developing over time.

18. Dawson Fingers

A classic MRI feature is Dawson fingers.

These are ovoid periventricular lesions oriented roughly perpendicular to the lateral ventricles along medullary veins.

They are strongly associated with MS but are not completely specific.

19. Visual Evoked Potentials

Visual evoked potentials (VEPs) measure electrical responses in the visual pathway after a visual stimulus.

Demyelination slows nerve conduction and can produce delayed P100 latency.

This can provide evidence of previous optic pathway demyelination even when the patient has recovered clinically.

VEPs are less central to diagnosis than MRI but can still be useful in selected cases.

20. CSF Oligoclonal Bands

CSF examination may reveal oligoclonal IgG bands that are present in the CSF but absent from serum.

This indicates intrathecal immunoglobulin production.

Oligoclonal bands are found in many patients with MS and can support the diagnosis.

However, they are not specific to MS and may occur in other inflammatory or infectious CNS disorders.

21. CSF IgG Index

The IgG index may also be raised.

Routine CSF findings are otherwise often relatively mild:

Glucose usually normal.

Protein normal or mildly raised.

White cells normal or mildly lymphocytic.

Marked pleocytosis or very high protein should prompt consideration of another diagnosis.

22. Modern Diagnosis

Modern diagnosis generally uses the McDonald criteria, which combine:

Clinical attacks.

MRI evidence.

Dissemination in space.

Dissemination in time.

CSF oligoclonal bands in appropriate circumstances.

The diagnosis also requires exclusion of better alternative explanations.

23. Management Principles

MS management is ideally multidisciplinary.

Care may involve:

Neurology.

Physiotherapy.

Occupational therapy.

Specialist nursing.

Ophthalmology.

Urology.

Rehabilitation services.

Psychological and social support.

Management includes acute relapse treatment, disease-modifying therapy, symptom control, and rehabilitation.

24. Acute Relapse Treatment

Significant acute relapses are commonly treated with high-dose corticosteroids.

A traditional regimen is intravenous methylprednisolone for 3–5 days, although high-dose oral regimens may also be used in appropriate settings.

Steroids accelerate recovery from the relapse but do not necessarily improve the ultimate long-term neurological outcome from that particular attack.

25. Disease-Modifying Therapy

Modern MS treatment includes a wide range of disease-modifying therapies (DMTs) designed to reduce relapse frequency, MRI activity, and disability accumulation.

These include injectable, oral, and monoclonal-antibody treatments.

Choice depends on disease activity, patient factors, pregnancy considerations, adverse-effect profile, monitoring requirements, and local guidelines.

26. Interferon-β

Interferon-beta was one of the earliest widely used disease-modifying therapies.

It can reduce:

Relapse frequency.

MRI inflammatory activity.

Disease activity in relapsing forms of MS.

However, it is no longer the only or necessarily preferred treatment because many newer DMTs are available.

27. Interferon-β and Secondary Progressive MS

The older statement that interferon-beta is routinely used in secondary progressive MS needs qualification.

Its benefit is mainly in relapsing disease with ongoing inflammatory activity.

In secondary progressive MS without active relapses or MRI inflammatory activity, interferon-beta is generally much less useful.

Modern treatment for active progressive disease may involve other disease-modifying agents depending on the exact phenotype and local approval.

28. Symptomatic Treatment

Symptom management is an important part of long-term care.

Examples include treatment for:

Spasticity.

Neuropathic pain.

Bladder dysfunction.

Fatigue.

Depression.

Mobility impairment.

Sexual dysfunction.

Physiotherapy and rehabilitation are often as important as medication for maintaining function and independence.

29. Multiple Sclerosis – Note Form

Definition: chronic immune-mediated inflammatory demyelinating disease of the CNS.

Pathology: inflammation + demyelination + axonal loss.

Diagnostic principle: lesions disseminated in space and time.

Common sites: periventricular, juxtacortical/cortical, infratentorial, spinal cord and optic nerve.

Weakness: often upper motor neurone type with spasticity and hyperreflexia.

Optic neuritis: painful subacute unilateral visual loss with red desaturation.

Sensory symptoms: paraesthesiae, numbness and Lhermitte phenomenon.

Diplopia: may result from internuclear ophthalmoplegia.

Bladder dysfunction: urgency, frequency, retention or incontinence may occur.

Vertigo/ataxia: due to brainstem or cerebellar lesions.

MRI: T2/FLAIR hyperintense white-matter lesions in characteristic locations.

Active lesions: may enhance with gadolinium.

VEP: delayed visual evoked response due to slowed conduction.

CSF: oligoclonal IgG bands present in CSF but not serum; not completely specific.

Acute relapse: high-dose corticosteroids such as methylprednisolone.

Long-term treatment: disease-modifying therapy selected according to disease type and activity.

Interferon-β: reduces relapses in relapsing forms of MS but is only one of many modern DMT options.

Key Clinical Pattern

Remember MS as:

Young adult + neurological episodes separated in time + lesions in different CNS locations.

The most useful clues are:

Optic neuritis.

Sensory disturbance.

Upper motor neurone weakness.

Internuclear ophthalmoplegia.

Ataxia.

Bladder dysfunction.

And the key investigations are:

MRI → characteristic T2/FLAIR lesions.

CSF → oligoclonal bands.

VEP → delayed conduction.

The core diagnostic concept is:

Multiple sclerosis = dissemination in space + dissemination in time.

Medicine – CSF Protein

CSF protein concentration rises when there is disruption of the blood–CSF barrier, inflammation, infection, impaired CSF circulation, tumour, or damage to nerve roots. The degree of elevation can therefore help narrow the differential diagnosis, although it is never interpreted in isolation.

Normal CSF protein is relatively low, typically around 0.15–0.45 g/L in adults, depending on the laboratory and age.

1. Markedly Raised CSF Protein

A markedly raised CSF protein, for example in the range of about 2–6 g/L, suggests a limited group of important disorders.

These include:

Guillain–Barré syndrome.

Spinal block, including tumour-related obstruction.

Tuberculous meningitis.

Fungal meningitis.

2. Guillain–Barré Syndrome

Guillain–Barré syndrome (GBS) classically produces:

High CSF protein + normal or only mildly raised white-cell count.

This is called albuminocytologic dissociation.

The protein rises because inflammation and demyelination of spinal nerve roots increase protein leakage into the CSF, while there is usually no large pleocytosis.

A useful examination pattern is:

Progressive ascending weakness + areflexia + high CSF protein with few cells = GBS.

3. Timing in Guillain–Barré Syndrome

An important point is that CSF protein may be normal early in GBS, particularly during the first few days.

It often rises after about the first week.

Therefore, a normal early CSF protein does not completely exclude GBS.

4. Spinal Block

A spinal block caused by a tumour or other obstructing lesion can produce a very high CSF protein.

The obstruction interferes with normal CSF circulation, allowing protein to accumulate below the level of the block.

This can sometimes produce a strikingly high protein concentration.

5. Froin Syndrome

Severe spinal CSF obstruction can produce Froin syndrome.

This is characterised by:

Very high CSF protein + xanthochromia + spontaneous clotting of CSF.

It occurs because stagnant CSF below a spinal block becomes concentrated with protein.

6. Tuberculous Meningitis

TB meningitis frequently causes a substantial rise in CSF protein.

The classic CSF pattern is:

Lymphocytes ↑ + protein ↑↑↑ + glucose ↓↓ + opening pressure ↑.

Protein may become very high because chronic meningeal inflammation disrupts the blood–CSF barrier.

7. Fungal Meningitis

Fungal meningitis, including cryptococcal meningitis, can also produce markedly elevated CSF protein.

The pattern often resembles TB meningitis:

Lymphocytes/mononuclear cells ↑ + protein ↑↑ + glucose ↓.

Opening pressure may also be raised, especially in cryptococcal disease.

8. Moderately Raised CSF Protein

A less extreme rise in CSF protein can occur in many neurological disorders.

Important causes include:

Bacterial meningitis.

Viral encephalitis or meningitis.

Cerebral abscess.

Multiple sclerosis.

Primary or metastatic cerebral tumours.

9. Bacterial Meningitis

In acute bacterial meningitis, CSF protein is commonly markedly elevated, often more than in viral disease.

The typical pattern is:

Neutrophils ↑↑ + glucose ↓↓ + protein ↑↑.

The protein rises because severe meningeal inflammation increases permeability of the blood–CSF barrier.

10. Viral Encephalitis

Viral encephalitis generally causes a mild to moderate rise in CSF protein.

The typical CSF pattern is:

Lymphocytes ↑ + protein ↑ + glucose usually normal.

HSV encephalitis may also produce red cells in the CSF because of haemorrhagic temporal-lobe necrosis.

11. Cerebral Abscess

A brain abscess may cause a moderate rise in CSF protein due to nearby inflammation or disruption of the blood–CSF barrier.

However, lumbar puncture is often not the key diagnostic test for suspected brain abscess and may be unsafe if there is raised intracranial pressure or mass effect.

Neuroimaging is usually more important.

12. Multiple Sclerosis

In multiple sclerosis, total CSF protein may be normal or mildly elevated.

A large protein rise is unusual and should prompt consideration of another diagnosis.

The more characteristic CSF findings in MS are:

CSF-restricted oligoclonal IgG bands.

Raised IgG index.

Mild lymphocytic pleocytosis in some cases.

13. Cerebral Tumours

Both primary brain tumours and cerebral metastases can raise CSF protein.

This may occur because of:

Disruption of the blood–CSF barrier.

Tumour involvement of the meninges.

Obstruction of CSF flow.

The degree of elevation varies widely.

14. Leptomeningeal Malignancy

When malignant cells spread to the meninges, CSF protein can be substantially raised.

Other findings may include:

Low CSF glucose.

Raised opening pressure.

Malignant cells on cytology.

Therefore, a high protein together with low glucose and abnormal cells should raise suspicion for leptomeningeal malignancy.

15. CSF Protein – Note Form

Markedly raised protein, around 2–6 g/L:

Guillain–Barré syndrome.

Spinal block.

TB meningitis.

Fungal meningitis.

Raised protein:

Bacterial meningitis.

Viral encephalitis/meningitis.

Cerebral abscess.

Multiple sclerosis, usually only mildly.

Primary or metastatic cerebral tumours.

16. High-Yield Patterns

GBS → high protein + few cells.

This is albuminocytologic dissociation.

TB meningitis → high protein + lymphocytes + low glucose.

Fungal meningitis → high protein + lymphocytes + low glucose.

Bacterial meningitis → high protein + neutrophils + low glucose.

Viral meningitis/encephalitis → moderately high protein + lymphocytes + normal glucose.

MS → protein normal or mildly raised + oligoclonal bands.

Key Clinical Pattern

The most useful way to remember CSF protein is:

Very high protein with few cells → GBS or spinal block.

Very high protein with lymphocytes and low glucose → TB or fungal meningitis.

High protein with neutrophils and low glucose → bacterial meningitis.

Mild/moderate protein rise with lymphocytes and normal glucose → viral infection.

Mild protein rise + oligoclonal bands → multiple sclerosis.

Medicine – Cells in Cerebrospinal Fluid (CSF)

The type of white blood cell present in cerebrospinal fluid provides an important clue to the underlying neurological disorder. The most useful distinction is between neutrophilic (polymorph) predominance and lymphocytic predominance.

However, cell patterns are not completely specific and can change with the stage of illness, prior antibiotic treatment, and underlying immune status.

1. Polymorphs in CSF

Polymorphs, meaning mainly neutrophils, are classically associated with acute bacterial meningitis.

The usual pattern is:

Neutrophils ↑↑ + protein ↑↑ + glucose ↓↓.

Bacterial Meningitis

In acute bacterial meningitis, the meninges become intensely inflamed and large numbers of neutrophils migrate into the CSF.

The cell count may rise into the hundreds or thousands per microlitre.

Common associated findings include:

Raised opening pressure.

Turbid CSF.

Low CSF glucose.

Markedly raised protein.

Important Exception

Neutrophils are not exclusive to bacterial meningitis.

Early viral meningitis, particularly during the first hours of illness, may sometimes show a temporary neutrophilic predominance before becoming lymphocyte-predominant.

Therefore, the full CSF pattern and clinical context must be considered.

2. Lymphocytes in CSF

A lymphocytic or mononuclear predominance is classically associated with viral, chronic infectious, inflammatory, malignant, or immune-mediated CNS disorders.

The major causes from your notes include:

Viral meningitis or encephalitis.

Partially treated bacterial meningitis.

CNS vasculitis.

HIV-associated neurological disease.

Leukaemia.

3. Viral Meningitis

Typical viral meningitis produces a lymphocytic pleocytosis.

The usual pattern is:

Lymphocytes ↑ + protein mildly/moderately ↑ + glucose usually normal.

Patients often present with headache, fever, photophobia, neck stiffness, and relatively preserved consciousness compared with severe bacterial meningitis.

4. Viral Encephalitis

Viral encephalitis also usually produces a lymphocyte-predominant CSF response.

However, because encephalitis involves the brain parenchyma rather than only the meninges, patients are more likely to have:

Altered consciousness.

Confusion or behavioural change.

Seizures.

Focal neurological deficits.

HSV Encephalitis

Herpes simplex virus encephalitis is an especially important cause.

CSF typically shows:

Lymphocytic pleocytosis.

Raised protein.

Usually normal glucose.

Red blood cells may sometimes be present because HSV encephalitis can cause haemorrhagic necrosis, particularly in the temporal lobes.

Diagnosis is usually supported by CSF HSV PCR.

5. Partially Treated Bacterial Meningitis

Bacterial meningitis that has already received antibiotics may show an altered CSF pattern.

The cell differential can become less typically neutrophilic and may become relatively lymphocyte-predominant.

Therefore:

Lymphocytes in CSF do not completely exclude bacterial meningitis, especially after prior antibiotic therapy.

Other findings such as low glucose and high protein may still support bacterial infection.

6. Tuberculous Meningitis

Although not listed in your current note, TB meningitis is one of the most important causes of lymphocytic CSF.

The classic pattern is:

Lymphocytes ↑ + protein ↑↑↑ + glucose ↓↓ + opening pressure ↑.

This is a high-yield distinction from uncomplicated viral meningitis.

7. Fungal Meningitis

Chronic fungal meningitis, including cryptococcal meningitis, also commonly causes a mononuclear or lymphocytic CSF pattern.

The typical combination is:

Lymphocytes/mononuclear cells ↑ + protein ↑ + glucose ↓.

This can closely resemble TB meningitis.

8. CNS Vasculitis

Central nervous system vasculitis may cause a mild inflammatory CSF picture.

CSF may show:

Lymphocytic pleocytosis.

Raised protein.

Glucose is usually relatively preserved.

These findings are nonspecific, so diagnosis depends on the broader clinical picture, imaging, laboratory tests, and occasionally vascular imaging or biopsy.

9. HIV-Associated Disease

Patients with HIV infection can develop a variety of CNS disorders associated with lymphocytes in the CSF.

This may occur with HIV itself or with opportunistic infections.

Examples include:

HIV-associated aseptic meningitis.

Cryptococcal meningitis.

Tuberculous meningitis.

Viral CNS infections.

Therefore, in an immunocompromised patient, CSF findings must be interpreted cautiously because inflammatory cell responses may sometimes be relatively modest despite severe infection.

10. Leukaemia

Leukaemia can involve the meninges and central nervous system.

Malignant cells may enter the CSF, producing leptomeningeal leukaemic involvement.

The CSF may contain increased mononuclear cells, but the key diagnostic issue is identifying abnormal malignant cells, rather than simply calling the response lymphocytic.

11. CSF Cytology

When malignant CNS involvement is suspected, CSF cytology is important.

Flow cytometry can also be especially valuable for detecting haematological malignancy involving the CSF.

In some cases, repeated lumbar punctures may be needed because malignant cells may not be detected in the first sample.

12. Other Causes of Lymphocytic CSF

Other important causes include:

Multiple sclerosis, which may produce a mild lymphocytic pleocytosis.

Neurosarcoidosis.

Syphilitic meningitis.

Lyme neuroborreliosis.

Autoimmune encephalitis.

These conditions generally produce much lower cell counts than acute bacterial meningitis.

13. Polymorphs – Note Form

Main association: acute bacterial meningitis.

Typical accompanying findings: low glucose + very high protein + raised opening pressure.

Important exception: early viral meningitis can temporarily show neutrophils.

14. Lymphocytes – Note Form

Viral meningitis: lymphocytes + normal glucose + moderately raised protein.

Viral encephalitis: lymphocytes + raised protein, usually normal glucose.

Partially treated bacterial meningitis: may become lymphocyte-predominant.

TB meningitis: lymphocytes + low glucose + very high protein.

Fungal meningitis: lymphocytes/mononuclear cells + low glucose + high protein.

CNS vasculitis: mild lymphocytic pleocytosis + raised protein.

HIV-associated CNS disease: often mononuclear/lymphocytic, but pattern depends on the underlying infection or process.

Leukaemia: malignant mononuclear cells may be present; confirm with cytology/flow cytometry.

Key Clinical Pattern

Remember:

Polymorphs/neutrophils → think bacterial meningitis.

Lymphocytes → think viral, TB, fungal, inflammatory, or malignant disease.

The fastest examination distinction is:

Neutrophils + low glucose → bacterial meningitis.

Lymphocytes + normal glucose → viral meningitis.

Lymphocytes + low glucose → TB or fungal meningitis.

Abnormal malignant cells → leukaemia or leptomeningeal malignancy.